Enhanced synthetic T cell receptors and antigen receptors

By modifying STAR molecules with costimulatory and cytokine receptor domains, the efficacy of T cells in cancer therapy is enhanced, addressing the limitations of impaired proliferation and activation in existing STAR technologies.

JP7591772B2Active Publication Date: 2024-11-29BRISTAR IMMUNOTECH LTD +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2022572623
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-12-24
Filing Date
2021-05-25
Publication Date
2024-11-29
Estimated Expiration
2041-05-25

AI Technical Summary

Technical Problem

Existing synthetic T cell receptors (STAR) lack costimulatory signals, leading to impaired proliferation and activation abilities, limiting their effectiveness in anti-solid tumor therapies.

Method used

Modifying the constant region, transmembrane domain, and endodomain of STAR molecules by introducing costimulatory molecule receptor endodomains, such as OX40 or ICOS, and cytokine receptor signaling domains to enhance T cell activation and proliferation.

Benefits of technology

Enhances the tumor-killing capacity, proliferation, and survival time of T cells, improving their performance in cancer therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591772000029
    Figure 0007591772000029
  • Figure 0007591772000030
    Figure 0007591772000030
  • Figure 0007591772000031
    Figure 0007591772000031
Patent Text Reader

Abstract

The present invention relates to the field of biopharmaceuticals, in particular to enhanced synthetic T cell receptors and antigen receptors (STARs) targeting CD19 and CD20, T cells comprising synthetic T cell receptor antigen receptors, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of biopharmaceuticals, in particular to enhanced synthetic T cell receptors and antigen receptors (STARs) targeting CD19 and CD20, T cells comprising synthetic T cell receptor antigen receptors, and uses thereof. [Background technology]

[0002] Cell therapy, especially T cell-related therapy, has developed rapidly this year, and among T cell-related therapies, chimeric antigen receptor T cell (CAR-T) therapy and TCR-T therapy have attracted much attention.

[0003] CAR-T therapy is based on the expression of CAR molecules in T cells. CAR molecules are composed of three parts: ectodomain (antigen recognition domain derived from antibody, and involved in target antigen recognition); transmembrane domain; and endodomain (signal molecule and costimulatory signal molecule derived from T cell receptor, and involved in transmitting T cell activation signal after receiving stimulation). When CAR molecules bind to their corresponding antigens, they aggregate, triggering the effector function of T cells and killing the target tumor cells.

[0004] TCR-T therapy is based on the T cell receptor (TCR). TCR is the main component of T cells, which can be divided into αβ T cells and γ δ T cells based on the type of TCR. During development, T precursor cells undergo VDJ rearrangement at the TCR γ chain and TCR δ chain, and develop into γδ T cells if the rearrangement is successful, or VDJ rearrangement at the TCR α chain and TCR β chain if the rearrangement is unsuccessful, and develop into αβ T cells. αβ T cells account for 90%-95% of peripheral blood T cells, while γ δ T cells account for 5%-10% of peripheral blood T cells. The two types of T cells recognize antigens in an MHC-restricted and MHC-unrestricted manner, respectively, and play important roles in immunity against pathogens and tumors.

[0005] T cell receptor (TCR) complex molecules contain multiple chains, among which TCR α and TCR β chains (or TCR γ and TCR δ chains) are involved in the recognition of MHC polypeptide molecules, and the other six CD3 subunits bind to the TCR α / β chains (or TCR γ / δ chains) to play a signal transduction role. The natural TCR complex contains 10 ITAM signal sequences, and theoretically can transmit stronger signals than CAR. By utilizing the signal transduction function of natural TCR, it is possible to construct a new receptor to alleviate the damage of T cells, which can perform better in the role of anti-solid tumors. The ectodomain of TCR is very similar to the Fab domain of antibody, and therefore it is possible to replace the variable region sequence of TCR with that of antibody to obtain a synthetic TCR and antigen receptor (STAR) that not only has antibody specificity, but also has the excellent signal transduction function of natural TCR in mediating the activation of T cells.

[0006] However, STAR-T derived from natural TCR lacks costimulatory signals for T cell activation and often has impaired proliferation and activation capabilities. Therefore, improved TCRs and corresponding TCR-T therapies are still needed in the field. [Brief description of the drawings]

[0007] [Figure 1] Schematic diagram of STAR optimization by constant region cysteine ​​engineering, transmembrane domain and endodomain engineering. [Diagram 2] Schematic diagram of the optimization of STAR by adding costimulatory molecule receptor endodomains to the α and / or β chains. [Diagram 3] Schematic diagram of the optimization of STAR by deletion of α and / or β chain endodomains followed by addition of costimulatory molecule receptor endodomains directly or via a linker. [Figure 4] Schematic diagram of the optimization of STAR by adding a costimulatory molecule receptor endodomain to the CD3 subunit. [Diagram 5] Schematic diagram of STAR optimization by adding cytokine receptor signaling domains to the α and / or β chains. [Figure 6] Comparison of tumor target cell killing ability between WT-STAR T cells and mut-STAR T cells. [Figure 7] Effect of various costimulatory receptor endodomains on the target killing capacity of STAR-T cells at different effector-to-target (E:T) ratios. [Figure 8] Effect of various costimulatory receptor endodomains on the target killing ability of STAR-T cells at different co-culture times. [Figure 9] Effect of the α-chain, β-chain, and OX40 endodomain appended to the α-chain and β-chain on the target killing ability of STAR-T cells at different E:T ratios. [Figure 10] Effect of the α-chain, β-chain, and OX40 endodomain appended to the α-chain and β-chain on the target killing capacity of STAR-T cells at different co-culture times. [Figure 11] Effects of various costimulatory receptor endodomains on cytokine secretion from STAR T cells. [Figure 12] Effects of various costimulatory receptor endodomains on the proliferation of STAR-T cells. [Figure 13] Effect of the α-chain, β-chain, and the OX40 endodomain appended to the α-chain and β-chain on the target killing ability of STAR-T cells. [Figure 14] Tumor-killing potential of mut-STAR with different costimulatory receptor endodomains linked to the TCR α chain. [Figure 15] Effect of various costimulatory receptor endodomains appended to different CD3 subunits on the target killing capacity of STAR T cells. [Figure 16] Effect of various costimulatory receptor endodomains appended to different CD3 subunits on STAR T cell proliferation. [Figure 17]Effect of OX40 endodomain linked to endodomain-deficient α-chain via different G4S linkers on the target killing capacity of STAR-T cells. [Figure 18] Effect of OX40 endodomain linked to endodomain-deficient β-chains via different G4S linkers on the target killing capacity of STAR-T cells. [Figure 19] Effect of OX40 endodomain linked to endodomain-deleted α and / or β chains via different G4S linkers on IL-2 secretion in STAR-T cells. [Figure 20] Effect of OX40 endodomain linked to endodomain-deleted α and / or β chains via different G4S linkers on IFN-γ secretion in STAR-T cells. [Figure 21] Effect of OX40 endodomain linked to endodomain-deficient α chain via different G4S linkers on central memory T cell differentiation. [Figure 22] Effect of OX40 endodomain linked to endodomain-deficient α-chain via different G4S linkers on T cell differentiation. [Figure 23] Effect of lysine modifications in the transmembrane or endodomain on the target killing capacity of STAR-T cells. [Figure 24] Effect of lysine modifications in the transmembrane domain or endodomain on IFN-γ secretion in STAR-T cells. [Diagram 25] Effect of lysine modifications in the transmembrane domain or endodomain on IL-2 secretion in STAR-T cells. [Figure 26] Effect of lysine modifications in the transmembrane domain or endodomain on central memory T cell differentiation. [Figure 27] Effect of lysine modifications in the transmembrane or endodomain on T cell differentiation. [Figure 28] Effect of various cytokine receptor signaling domains linked to the α and / or β chains on the target killing capacity of STAR-T cells. [Figure 29] Comparison of killing effects between mutant STAR and α-del-(G4S)3-OX40-STAR linked to different cytokine receptor stimulatory domains. [Diagram 30] Effect of various cytokine receptor signaling domains linked to the α and / or β chains on IL-2 secretion in STAR T cells. [Diagram 31] Effect of various cytokine receptor signaling domains linked to the α and / or β chains on IFN-γ secretion in STAR T cells. [Diagram 32] Effects of various cytokine receptor signaling domains linked to the α and / or β chains on central memory T cell differentiation. [Diagram 33] Effects of various cytokine receptor signaling domains linked to the α and / or β chains on T cell differentiation. [Diagram 34] Antitumor in vivo effects of αβOX40-STAR T, mut-STAR T and CAR-T in mouse tumor models in vivo. [Diagram 35] Survival curves of mice administered αβOX40-STAR T, mut-STAR T and CAR-T. [Diagram 36] In vivo expansion of αβOX40-STAR T, mut-STAR T and CAR-T in mice. [Figure 37] Antitumor in vivo efficacy of various STAR constructs and CAR-T in mouse tumor models. [Figure 38] Schematic diagram of the optimization of STAR by constant region cysteine ​​engineering, transmembrane domain and N-terminal rearrangement. [Figure 39] Example of linkage locations between costimulatory molecule domains and STAR structures. Only links to the α chain are shown. [Diagram 40] Examples of STAR structures containing costimulatory molecule domains. [Diagram 41] Killing potential of STAR, including STAR and costimulatory factors. [Diagram 42]Nuclear RELB levels correlate with STAR proliferation signals, including STAR and costimulatory factors. [Diagram 43] Results for various anti-CD19 STARs. [Diagram 44] Results for various STARs, anti-CD19 and anti-CD20, with costimulatory factors attached to the α and β chains. [Diagram 45] Results for anti-CD19 and anti-CD20STAR where the costimulatory factor was attached to the α chain. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] Unless otherwise indicated or defined, all terms used have the general meaning in the art as understood by those skilled in the art. For example, see standard manuals such as "Molecular cloning: a laboratory manual" by Sambrook et al., "Genes VIII" by Lewin, and "Immunology" (8th edition) by Roitt et al., and the general prior art cited herein; in addition, unless otherwise stated, all methods, steps, techniques, and operations should be understood by those skilled in the art without being specifically detailed, and can and have been carried out in a manner known per se. For example, see standard manuals, the general prior art mentioned above, and other references cited therein.

[0009] As used herein, the term "and / or" includes all combinations of the items connected by the term and should be recognized as individually listed herein. For example, "A and / or B" covers "A," "A and B," and "B." For example, "A, B, and / or C" covers "A," "B," "C," "A and B," "A and C," "B and C," and "A and B and C."

[0010] The term "comprising" is used herein to describe a protein or nucleic acid sequence, which may consist of said sequence or may have additional amino acids or nucleotides at one or both ends of said protein or nucleic acid, but still have the activity described herein. In addition, those skilled in the art will understand that the methionine encoded by the start codon at the N-terminus of a polypeptide may be retained in certain practical situations (e.g., when expressed in a particular expression system), but without substantially affecting the function of the polypeptide. Thus, when describing a particular polypeptide amino acid sequence, it is still intended to encompass sequences that do not contain the methionine encoded by the start codon at the N-terminus of the particular polypeptide amino acid sequence, but do contain a methionine to some extent, and similarly, the coding nucleotide sequence of a particular polypeptide amino acid sequence may also contain a start codon, but vice versa.

[0011] As used herein, "amino acid number linked to SEQ ID NO: x" (SEQ ID NO: x is a specific sequence listed herein) means that the position number of a particular amino acid described is the position number of the amino acid corresponding to that amino acid on SEQ ID NO: x. Amino acid correspondence between different amino acid sequences can be determined by sequence alignment methods known in the art. For example, amino acid correspondence can be determined by the EMBL-EBI online alignment tool (https: / / www.ebi.ac.uk / Tools / psa / ), where two sequences can be aligned using the Needleman-Wunsch algorithm with default parameters. For example, starting from the N-terminus of a polypeptide, if an alanine at position 46 is aligned with an amino acid at position 48 of SEQ ID NO: x in a sequence alignment, the amino acid in the polypeptide can also be described herein as "an alanine at position 48 of the polypeptide, but at the amino acid position linked to SEQ ID NO: x". In the present invention, for amino acid positions associated with the alpha chain constant region, SEQ ID NO: 3 is linked. In the present invention, SEQ ID NO:4 is linked to amino acid positions associated with the β chain constant region.

[0012] In one aspect, provided herein is a modified T cell receptor (TCR) complex, wherein i) the TCR may be an αβ TCR, the αβ TCR complex comprising a TCR α chain, a TCR β chain, CD3 ε, CD3 γ, CD3 δ and CD3 ζ, and at least one functional domain is linked to the C-terminus of at least one of the TCR α chain, the TCR β chain, CD3 ε, CD3 γ, CD3 δ and CD3 ζ; the TCR α chain comprises a first constant region and a first antigen-binding region, and the TCR β chain comprises a second constant region and a second antigen-binding region; the first antigen-binding region specifically binds to a first antigen and the second antigen-binding region specifically binds to a second antigen, or the first antigen-binding region and the second antigen-binding region in combination with each other specifically bind to the first antigen and the second antigen, preferably, the first antigen is CD19 and the second antigen is CD20, or the first antigen is CD20 and the second antigen is CD19; Or, ii) the TCR may be a gamma delta TCR, the gamma delta TCR complex comprising a TCR gamma chain, a TCR delta chain, CD3 epsilon, CD3 gamma, CD3 delta, and CD3 zeta; and at least one functional domain is linked to the C-terminus of at least one of the TCR gamma chain, the TCR delta chain, CD3 epsilon, CD3 gamma, CD3 delta, and CD3 zeta; the TCR γ chain comprises a first constant region and a first antigen-binding region, and the TCR δ chain comprises a second constant region and a second antigen-binding region; The first antigen-binding region specifically binds to a first antigen and the second antigen-binding region specifically binds to a second antigen, or the first antigen-binding region and the second antigen-binding region in combination with each other specifically bind to the first antigen and the second antigen, preferably, the first antigen is CD19 and the second antigen is CD20, or the first antigen is CD20 and the second antigen is CD19.

[0013] Generally, in the TCR, the antigen binding region is located N-terminal to the constant region, and both may be linked directly or via a linker.

[0014] In one embodiment, a modified T cell receptor (TCR) is provided, wherein the TCR comprises: i) an αβ TCR comprising a TCR α chain and a TCR β chain, wherein at least one functional domain is linked to the C-terminus of the TCR α chain and / or the TCR β chain of said αβ TCR; the TCR α chain comprises a first constant region and a first antigen-binding region, and the TCR β chain comprises a second constant region and a second antigen-binding region; an αβ TCR, wherein the first antigen-binding region specifically binds to a first antigen and the second antigen-binding region specifically binds to a second antigen, or the first antigen-binding region and the second antigen-binding region in combination with each other specifically bind to the first antigen and the second antigen, preferably, the first antigen is CD19 and the second antigen is CD20, or the first antigen is CD20 and the second antigen is CD19; Or, ii) a γδ TCR comprising a TCR γ chain and a TCR δ chain, wherein at least one functional domain is linked to the C-terminus of the TCR γ chain and / or the TCR δ chain of the γδ TCR; the TCR γ chain comprises a first constant region and a first antigen-binding region, and the TCR δ chain comprises a second constant region and a second antigen-binding region; a γδ TCR, wherein the first antigen-binding region specifically binds to a first antigen and the second antigen-binding region specifically binds to a second antigen, or the first antigen-binding region and the second antigen-binding region specifically bind to the first antigen and the second antigen in combination with each other, preferably the first antigen is CD19 and the second antigen is CD20, or the first antigen is CD20 and the second antigen is CD19. It could be.

[0015] In some embodiments, at least one of the native endodomains of the TCR α chain, TCR β chain, CD3 epsilon, CD3 gamma, CD3 delta, and CD3 zeta in the αβ TCR complex is deleted, or at least one of the native endodomains of the TCR gamma chain, TCR delta chain, CD3 epsilon, CD3 gamma, CD3 delta, and CD3 zeta in the γδ TCR complex is deleted.

[0016] In some embodiments the native endodomains of the TCR α and / or TCR β chain in an αβ TCR are deleted, or the native endodomains of the TCR γ and / or TCR δ chain in a γδ TCR are deleted.

[0017] In some embodiments, in the αβ TCR complex, a functional domain is linked directly or via a linker to the C-terminus of at least one of the TCR α chain, the TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ that lacks a native endodomain.

[0018] In some embodiments, in the αβ TCR complex, the functional domain is linked, either directly or via a linker, to the C-terminus of the TCR α chain and the TCR β chain, which have the native endodomain deleted.

[0019] In some embodiments, in the γδ TCR complex, a functional domain is linked directly or via a linker to the C-terminus of at least one of the TCR α chain, the TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ, which lacks a native endodomain.

[0020] In some embodiments, in the γδ TCR complex, the functional domain is linked, directly or via a linker, to the C-terminus of at least one of the TCR γ chain, the TCR δ chain, which lacks its native endodomain.

[0021] In some embodiments, the linker is (G4S)n, where n represents an integer from 1 to 10. Preferably, n is an integer from 1 to 6, more preferably, n is an integer from 2 to 5, and most preferably, n is 3.

[0022] In some embodiments, at least one functional domain is linked to the C-terminus of one of the TCR α chain, the TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ within the αβ TCR complex.

[0023] In some embodiments, at least one functional domain is linked to the C-terminus of the TCR α chain and / or the TCR β chain within an αβ TCR.

[0024] In some embodiments, at least one functional domain is linked to the C-terminus of one of the TCR γ chain, the TCR δ chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ within the γδ TCR complex.

[0025] In some embodiments, at least one functional domain is linked to the C-terminus of the TCR γ chain and / or the TCR δ chain within a γδ TCR.

[0026] In some embodiments, CD3 delta, CD3 gamma, CD3 epsilon, and CD3 zeta within the TCR complex do not comprise at least one functional domain further linked to their C-terminus.

[0027] In some embodiments, at least one functional domain is linked to the C-terminus of the TCR α chain within the αβ TCR complex.

[0028] In some embodiments, at least one functional domain is linked to the C-terminus of the TCR α chain in an αβ TCR.

[0029] In some embodiments, the native endodomain of the TCR α chain is deleted.

[0030] In some embodiments, the functional domain is linked directly or via a linker to the C-terminus of a TCR α-chain lacking the native endodomain. In some embodiments, the linker is (G4S)n, where n represents an integer between 1 and 10, preferably between 1 and 6, more preferably between 2 and 5, and most preferably, n is 3.

[0031] In some embodiments, at least one functional domain is linked to the C-terminus of a TCR β chain within the αβ TCR complex.

[0032] In some embodiments, at least one functional domain is linked to the C-terminus of a TCR β chain in an αβ TCR.

[0033] In some embodiments, the native endodomain of the TCR β chain is deleted.

[0034] In some embodiments, the functional domain is linked directly or via a linker to the C-terminus of a TCR β chain lacking a native endodomain. In some embodiments, the linker is (G4S)n, where n represents an integer between 1 and 10, preferably between 1 and 6, more preferably between 2 and 5, and most preferably, n is 3.

[0035] In some embodiments, at least one functional domain is linked to the C-terminus of the TCR gamma chain within the γδ TCR complex.

[0036] In some embodiments, at least one functional domain is linked to the C-terminus of the TCR gamma chain in a γδ TCR.

[0037] In some embodiments, the native endodomain of the TCR gamma chain is deleted.

[0038] In some embodiments, the functional domain is linked directly or via a linker to the C-terminus of a TCR γ chain lacking a native endodomain, in some embodiments the linker is (G4S)n, where n represents an integer between 1 and 10, preferably between 1 and 6, more preferably between 2 and 5, and most preferably n is 3.

[0039] In some embodiments, at least one functional domain is linked to the C-terminus of the TCR δ chain within the γδ TCR complex.

[0040] In some embodiments, at least one functional domain is linked to the C-terminus of the TCR δ chain in a γδ TCR.

[0041] In some embodiments, the native endodomain of the TCR δ chain is deleted.

[0042] In some embodiments, the functional domain is linked directly or via a linker to the C-terminus of a TCR δ chain lacking a native endodomain, in some embodiments the linker is (G4S)n, where n represents an integer between 1 and 10, preferably between 1 and 6, more preferably between 2 and 5, and most preferably n is 3.

[0043] In some embodiments, at least one functional domain is linked to the C-terminus of two of the TCR α chain, the TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ within the αβ TCR complex.

[0044] In some embodiments, at least one functional domain is linked to the C-terminus of two of the TCR γ chain, the TCR δ chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ within the γδ TCR complex.

[0045] In some embodiments, at least one functional domain is linked to the C-terminus of each of the TCR α chain and the TCR β chain within the αβ TCR complex.

[0046] In some embodiments, at least one functional domain is linked to the C-terminus of each of the TCR α chain and the TCR β chain in an αβ TCR.

[0047] In some embodiments, the native endodomains of each of the TCR α and β chains are deleted.

[0048] In some embodiments, the functional domains are linked directly or via a linker to the C-terminus of each of the TCR α and β chains lacking the native endodomain. In some embodiments, the linker is (G4S)n, where n represents an integer between 1 and 10, preferably between 1 and 6, more preferably between 2 and 5, and most preferably, n is 3.

[0049] In some embodiments, at least one functional domain is linked to each C-terminus of the TCR γ chain and the TCR δ chain within the γδ TCR complex.

[0050] In some embodiments, at least one functional domain is linked to the C-terminus of each of the TCR γ chain and the TCR δ chain in a γδ TCR.

[0051] In some embodiments, the native endodomains of each of the TCR gamma and delta chains are deleted.

[0052] In some embodiments, the functional domain is linked directly or via a linker to the C-terminus of each of the TCR γ and TCR δ chains lacking the native endodomain. In some embodiments, the linker is (G4S)n, where n represents an integer between 1 and 10, preferably between 1 and 6, more preferably between 2 and 5, and most preferably, n is 3.

[0053] In some embodiments, two or more of the TCR α chain, TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ within the αβ TCR complex are linked to the same or different functional domains.

[0054] In some embodiments, the TCR α chain and / or the TCR β chain within an αβ TCR are linked to the same or different functional domains.

[0055] In some embodiments, two or more of the TCR γ chain, TCR δ chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ within a γδ TCR complex are linked to the same or different functional domains.

[0056] In some embodiments, the TCR γ chain and / or the TCR δ chain within a γδ TCR are linked to the same or different functional domains.

[0057] In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more functional domains are linked to the C-terminus of at least one of the TCR α chain, the TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ within the αβ TCR complex.

[0058] In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more functional domains are linked to the C-terminus of the TCR α chain and / or the TCR β chain within an αβ TCR.

[0059] In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more functional domains are linked to the C-terminus of at least one of the TCR γ chain, the TCR δ chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ within the γδ TCR complex.

[0060] In some embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more functional domains are linked to the C-terminus of the TCR γ chain and / or the TCR δ chain in a γδ TCR.

[0061] In some embodiments, at least one functional domain, such as a costimulatory molecule endodomain, is linked to the C-terminus of one, two, three, four, five, or six of the TCR α chain, TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ in the complex.

[0062] In some preferred embodiments, at least one functional domain, such as a costimulatory molecule endodomain, is linked to the C-terminus of one of the TCR α chain, TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ in the complex.

[0063] For example, in some embodiments, at least one functional domain, such as a costimulatory molecule endodomain, is linked to the C-terminus of the TCR α chain in the complex. In some preferred embodiments, the costimulatory molecule endodomain is OX40 or ICOS. In some embodiments, the TCR β chain, CD3 δ, CD3 γ, CD3 ε, and CD3 ζ may not contain at least one functional domain, such as a costimulatory molecule endodomain, further linked to their C-terminus.

[0064] Alternatively, in some embodiments, at least one functional domain, such as a costimulatory molecule endodomain, is linked to the C-terminus of CD3δ within the complex, hi some embodiments, TCR α, TCR β, CD3 γ, CD3 ε, and CD3 ζ may not contain at least one functional domain, such as a costimulatory molecule endodomain, linked to their C-terminus.

[0065] In some preferred embodiments, at least one functional domain, such as a costimulatory molecule endodomain, is linked to the C-terminus of two of the TCR α chain, TCR β chain, CD3 ε, CD3 γ, CD3 δ, and CD3 ζ in the complex.

[0066] For example, in some embodiments, at least one functional domain, such as a costimulatory molecule endodomain, is linked to the C-terminus of the TCR α and TCR β chains in the complex. In some preferred embodiments, the costimulatory molecule endodomain is OX40 or ICOS. In some embodiments, CD3 δ, CD3 γ, CD3 ε, and CD3 ζ do not contain at least one functional domain, such as a costimulatory molecule endodomain, further linked to their C-terminus.

[0067] In some embodiments, the functional domain is an exogenous functional domain. In some embodiments, the functional domain is an exogenous endodomain, such as a domain involved in an intracellular signaling function.

[0068] As used herein, "exogenous" refers to a protein or nucleic acid sequence that originates from a foreign species or, if from the same species, that has undergone significant change in composition and / or location from the naturally occurring form of the protein or nucleic acid sequence through deliberate human intervention.

[0069] As used herein, a "functional domain" is selected from the endodomains of costimulatory molecules, such as CD40, OX40, ICOS, CD28, 4-1BB, CD27, and CD137, or co-inhibitory molecules, such as TIM3, PD1, CTLA4, and LAG3, or the endodomains of cytokine receptors, such as interleukin receptors (e.g., IL-2 receptor, IL-7α receptor, or IL-21 receptor), interferon receptors, tumor necrosis factor superfamily receptors, colony stimulating factor receptors, chemokine receptors, growth factor receptors, or other membrane proteins, or domains of intracellular proteins, such as NIK. A functional domain can also be a fusion of a cytokine receptor endodomain with a human STAT5 activating portion (amino acid sequence represented by SEQ ID NO: 35), either directly or via a linker (e.g., (G4S)n, where n represents an integer between 1 and 10).

[0070] In some preferred embodiments, the functional domain is a costimulatory molecule endodomain, preferably an OX40 endodomain or an ICOS endodomain, and more preferably an OX40 endodomain.

[0071] An exemplary CD40 endodomain contains the amino acid sequence represented by SEQ ID NO: 10. An exemplary OX40 endodomain contains the amino acid sequence represented by SEQ ID NO: 11. An exemplary ICOS endodomain contains the amino acid sequence represented by SEQ ID NO: 12. An exemplary CD28 endodomain contains the amino acid sequence represented by SEQ ID NO: 13. An exemplary 4-1BB endodomain contains the amino acid sequence represented by SEQ ID NO: 14. An exemplary CD27 endodomain contains the amino acid sequence represented by SEQ ID NO: 15. An exemplary IL-2β receptor endodomain contains the amino acid sequence represented by SEQ ID NO: 32. An exemplary IL-17α receptor endodomain contains the amino acid sequence represented by SEQ ID NO: 33. An exemplary IL-21 receptor endodomain contains the amino acid sequence represented by SEQ ID NO: 34. An exemplary fusion amino acid sequence of an IL-2β receptor endodomain and a human STAT5 activating moiety is represented by SEQ ID NO: 36. An exemplary fusion amino acid sequence of an IL-17α receptor endodomain and a human STAT5 activating moiety is represented by SEQ ID NO: 37.

[0072] In some embodiments, the first constant region is a native TCR alpha chain constant region, such as a native human TCR alpha chain constant region (an exemplary human TCR alpha chain constant region amino acid sequence is represented by SEQ ID NO:1) or a native mouse TCR alpha chain constant region (an exemplary mouse TCR alpha chain constant region amino acid sequence is represented by SEQ ID NO:3), or the first constant region is a native TCR gamma chain constant region, such as a native human TCR gamma chain constant region (an exemplary human TCR gamma chain constant region amino acid sequence is represented by SEQ ID NO:50) or a native mouse TCR gamma chain constant region (an exemplary mouse TCR gamma chain constant region amino acid sequence is represented by SEQ ID NO:51).

[0073] In some embodiments, the first constant region is a modified TCR alpha chain constant region or a modified TCR gamma chain constant region.

[0074] In some embodiments, the modified TCR alpha chain constant region is derived from a mouse TCR alpha chain constant region in which the amino acid at position 48, such as threonine (T), has been mutated to cysteine ​​(C) compared to the wild-type mouse TCR alpha chain constant region.

[0075] In some embodiments, the modified TCR alpha chain constant region is derived from a mouse TCR alpha chain constant region in which, compared to the wild-type mouse TCR alpha chain constant region, the amino acid at position 112, such as serine (S), is mutated to leucine (L), the amino acid at position 114, such as methionine (M), is mutated to isoleucine (I), and the amino acid at position 115, such as glycine (G), is mutated to valine (V).

[0076] In some embodiments, the modified TCR α chain constant region is derived from a mouse TCR α chain constant region in which, compared to the wild-type mouse TCR α chain constant region, the amino acid at position 6 (e.g., E) is replaced with D, K at position 13 is replaced with R, and amino acids at positions 15 to 18 are deleted.

[0077] In some embodiments, the modified TCR alpha chain constant region is derived from a mouse TCR alpha chain constant region in which, compared to the wild-type mouse TCR alpha chain constant region, the amino acid at position 48, such as threonine (T), is mutated to cysteine ​​(C), the amino acid at position 112, such as serine (S), is mutated to leucine (L), the amino acid at position 114, such as methionine (M), is mutated to isoleucine (I), and the amino acid at position 115, such as glycine (G), is mutated to valine (V).

[0078] In some embodiments, the modified TCR α-chain constant region is derived from a mouse TCR α-chain constant region in which, compared to the wild-type mouse TCR α-chain constant region, the amino acid at position 6 (e.g., E) is substituted with D, K at position 13 is substituted with R, amino acids at positions 15 to 18 are deleted, the amino acid at position 48, such as threonine (T), is mutated to cysteine ​​(C), the amino acid at position 112, such as serine (S), is mutated to leucine (L), the amino acid at position 114, such as methionine (M), is mutated to isoleucine (I), and the amino acid at position 115, such as glycine (G), is mutated to valine (V).

[0079] In some embodiments, the modified TCR α chain constant region is derived from a mouse TCR α chain constant region that lacks the constant region endodomain, e.g., amino acids 136-137, compared to a wild-type mouse TCR α chain constant region.

[0080] In some embodiments, the first constant region comprises an amino acid sequence represented by one of SEQ ID NOs: 1, 3, 5, 7, 8, 26, 41, 42, and 56.

[0081] In some embodiments, the second constant region is a native TCR β chain constant region, such as a native human TCR β chain constant region (an exemplary human TCR β chain constant region amino acid sequence is represented by SEQ ID NO:2) or a native mouse TCR β chain constant region (an exemplary mouse TCR β chain constant region amino acid sequence is represented by SEQ ID NO:4), or the second constant region is a native TCR δ chain constant region, such as a native human TCR δ chain constant region (an exemplary human TCR δ chain constant region amino acid sequence is represented by SEQ ID NO:52) or a native mouse TCR δ chain constant region (an exemplary mouse TCR δ chain constant region amino acid sequence is represented by SEQ ID NO:53).

[0082] In some embodiments, the second constant region is a modified TCR β chain constant region or a modified TCR δ chain constant region.

[0083] In some embodiments, the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which the amino acid at position 56, such as threonine (S), has been mutated to cysteine ​​(C) compared to the wild-type mouse TCR β chain constant region.

[0084] In some embodiments, the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which, compared to the wild-type mouse TCR β chain constant region, the amino acid at position 3 (e.g., R) is replaced with K, the amino acid at position 6 (e.g., T) is replaced with F, K at position 9 is replaced with E, S at position 11 is replaced with A, L at position 12 is replaced with V, and amino acids at positions 17 and 21 to 25 are deleted.

[0085] In some embodiments, the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which, compared to the wild-type mouse TCR β chain constant region, the amino acid at position 56, such as serine (S), is mutated to cysteine ​​(C), the amino acid at position 3 (e.g., R) is substituted with K, the amino acid at position 6 (e.g., T) is substituted with F, the K at position 9 is substituted with E, the S at position 11 is substituted with A, the L at position 12 is substituted with V, and the amino acids at positions 17 and 21 to 25 are deleted.

[0086] In some embodiments, the modified TCR β chain constant region is derived from a mouse TCR β chain constant region that lacks the constant region endodomain, e.g., amino acids 167 to 172, compared to a wild-type mouse TCR β chain constant region.

[0087] In some embodiments, the modified TCR β chain constant region comprises an amino acid sequence represented by one of SEQ ID NOs: 2, 4, 6, 9, 27, 43, and 49.

[0088] "Antigen-binding region" refers to a domain capable of specifically binding to a target antigen, either alone or in combination with another antigen-binding region.

[0089] In some embodiments, the antigen-binding region is derived from an antibody that specifically binds to a target antigen.

[0090] In some embodiments, the first antigen-binding region or the second antigen-binding region has the ability to bind specifically to the same or different target antigens independently, e.g., the first antigen-binding region specifically binds to the first antigen, and the second antigen-binding region specifically binds to the second antigen. In some embodiments, the antigen-binding region is a single chain antibody (e.g., scFv) or a single domain antibody (e.g., camelid antibody), and preferably, the antigen-binding region is a single chain antibody, e.g., scFv. In certain embodiments, the single chain antibody comprises a heavy chain variable region and a light chain variable region linked via a linker. In some embodiments, the linker is (G4S)n, where n represents an integer from 1 to 10, and preferably, n is 1 or 3.

[0091] In some embodiments, the antigen-binding region that specifically binds to CD19 comprises the heavy chain variable region amino acid sequence represented by SEQ ID NO: 44 and the light chain variable region amino acid sequence represented by SEQ ID NO: 45. In certain embodiments, the heavy chain variable region amino acid sequence represented by SEQ ID NO: 44 and the light chain variable region amino acid sequence represented by SEQ ID NO: 45 are linked via a linker. In some embodiments, the linker is (G4S)n, where n represents an integer of 1 to 10, preferably 1 or 3.

[0092] In some embodiments, the antigen-binding region that specifically binds to CD19 comprises the heavy chain variable region amino acid sequence represented by SEQ ID NO: 46 and the light chain variable region amino acid sequence represented by SEQ ID NO: 47. In some embodiments, the heavy chain variable region amino acid sequence represented by SEQ ID NO: 46 and the light chain variable region amino acid sequence represented by SEQ ID NO: 47 are linked via a linker. In some embodiments, the linker is (G4S)n, where n represents an integer of 1 to 10, and preferably n is 1 or 3.

[0093] In some embodiments, the antigen-binding region that specifically binds to CD19 comprises the scFv amino acid sequence set forth in SEQ ID NO:39.

[0094] In some embodiments, the antigen-binding region that specifically binds to CD20 comprises the heavy chain variable region amino acid sequence represented by SEQ ID NO: 54 and the light chain variable region amino acid sequence represented by SEQ ID NO: 55. In some embodiments, the heavy chain variable region amino acid sequence represented by SEQ ID NO: 54 and the light chain variable region amino acid sequence represented by SEQ ID NO: 55 are linked via a linker. In some embodiments, the linker is (G4S)n, where n represents an integer of 1 to 10, and preferably n is 1 or 3.

[0095] In some embodiments, the antigen-binding region that specifically binds to CD20 comprises the heavy chain variable region amino acid sequence represented by SEQ ID NO: 56 and the light chain variable region amino acid sequence represented by SEQ ID NO: 57. In certain embodiments, the heavy chain variable region amino acid sequence represented by SEQ ID NO: 56 and the light chain variable region amino acid sequence represented by SEQ ID NO: 57 are linked via a linker. In some embodiments, the linker is (G4S)n, where n represents an integer of 1 to 10, and preferably n is 1 or 3.

[0096] In some embodiments, the antigen-binding region that specifically binds to CD20 comprises the scFv amino acid sequence set forth in SEQ ID NO:38.

[0097] In some embodiments, the first antigen-binding region and the second antigen-binding region specifically bind to a target antigen in combination with each other, for example, the first antigen-binding region comprises an antibody heavy chain while the second antigen-binding region comprises an antibody light chain, or vice versa.

[0098] In some embodiments, the first antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, while the second antigen-binding region comprises an antibody light chain variable region that specifically binds to the first antigen and an antibody light chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region combine with each other to specifically bind to both the first antigen and the second antigen.

[0099] In some embodiments, the first antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody light chain variable region that specifically binds to the second antigen, while the second antigen-binding region comprises an antibody light chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region combine with each other to specifically bind to both the first antigen and the second antigen.

[0100] In some embodiments, the first antigen-binding region comprises an antibody light chain variable region that specifically binds to a first antigen and an antibody light chain variable region that specifically binds to a second antigen, while the second antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region combine with each other to specifically bind to both the first antigen and the second antigen.

[0101] In some preferred embodiments, the first antigen is CD19 and the second antigen is CD20. Alternatively, in some preferred embodiments, the first antigen is CD20 and the second antigen is CD19.

[0102] In certain embodiments, the antibody heavy chain variable region that specifically binds to CD19 comprises the amino acid sequence represented by SEQ ID NO:44, and the light chain variable region comprises the amino acid sequence represented by SEQ ID NO:45.

[0103] In certain embodiments, the antibody heavy chain variable region that specifically binds to CD19 comprises the amino acid sequence represented by SEQ ID NO:46, and the light chain variable region comprises the amino acid sequence represented by SEQ ID NO:47.

[0104] In certain embodiments, an antibody heavy chain variable region that specifically binds to CD20 comprises the amino acid sequence represented by SEQ ID NO:54, and a light chain variable region comprises the amino acid sequence represented by SEQ ID NO:55.

[0105] In certain embodiments, an antibody heavy chain variable region that specifically binds to CD20 comprises the amino acid sequence represented by SEQ ID NO:56, and a light chain variable region comprises the amino acid sequence represented by SEQ ID NO:57.

[0106] In some embodiments, CD3γ, CD3δ, CD3ε, and / or CD3ζ are human CD3γ, CD3δ, CD3ε, and / or CD3ζ. In some embodiments, the human CD3γ comprises the amino acid sequence represented by SEQ ID NO:28. In some embodiments, the human CD3γ comprises the amino acid sequence represented by SEQ ID NO:29. In some embodiments, the human CD3γ comprises the amino acid sequence represented by SEQ ID NO:30. In some embodiments, the human CD3γ comprises the amino acid sequence represented by SEQ ID NO:31.

[0107] In some embodiments, a modified T cell receptor (TCR) or TCR complex of the present invention comprises a TCR alpha chain as represented by SEQ ID NO:59, and a TCR beta chain as represented by SEQ ID NO:60.

[0108] In another aspect, provided herein is an isolated therapeutic immune cell comprising an engineered T cell receptor (TCR) or TCR complex of the invention.

[0109] In some embodiments, the immune cell is a T cell. In other embodiments, the immune cell is a NK cell.

[0110] In another aspect, the present invention provides an isolated polynucleotide comprising a nucleotide sequence encoding at least one of the TCR alpha chain, TCR beta chain, TCR gamma chain, TCR delta chain, CD3 epsilon, CD3 gamma, CD3 delta and CD3 zeta as defined above, wherein at least one exogenous functional endodomain is linked to the C-terminus of at least one of the TCR alpha chain, TCR beta chain, TCR gamma chain, TCR delta chain, CD3 epsilon, CD3 gamma, CD3 delta and CD3 zeta.

[0111] In another aspect, the present invention provides an isolated polynucleotide comprising a nucleotide sequence encoding a TCR as defined above.

[0112] In some embodiments, the isolated polynucleotide comprises a nucleotide sequence encoding a TCR α chain and / or a TCR β chain linked at its C-terminus to at least one costimulatory molecule endodomain.

[0113] In some embodiments, the polynucleotide comprises i) a nucleotide sequence encoding an alpha chain, ii) a nucleotide sequence encoding a beta chain, and iii) a nucleotide sequence encoding a self-cleaving peptide located between i) and ii) in the same reading frame. The nucleotide sequence encoding the alpha chain may be located at the 5' or 3' end of the nucleotide sequence encoding the beta chain.

[0114] In some embodiments, the isolated polynucleotide comprises a nucleotide sequence encoding a TCR gamma chain and / or a TCR delta chain linked at its C-terminus to at least one costimulatory molecule endodomain.

[0115] In some embodiments, the polynucleotide comprises i) a nucleotide sequence encoding a gamma chain, ii) a nucleotide sequence encoding a delta chain, and iii) a nucleotide sequence encoding a self-cleaving peptide located between i) and ii) in the same reading frame. The nucleotide sequence encoding the gamma chain may be located at the 5' or 3' end of the nucleotide sequence encoding the delta chain.

[0116] As used herein, "self-cleaving peptide" refers to a peptide that can carry out self-cleavage within a cell. For example, the self-cleaving peptide may contain a protease recognition site such that it is recognized and specifically cleaved by a protease within the cell.

[0117] Alternatively, the self-cleaving peptide can be a 2A polypeptide. The 2A polypeptide is a type of short peptide from a virus, and the self-cleavage of the 2A polypeptide occurs during translation. When two different target proteins are linked by the 2A polypeptide and expressed in the same reading frame, the two target proteins are produced in an approximately 1:1 ratio. Common 2A polypeptides can be P2A from porcine techovirus-1, T2A from Thosea asigna virus, E2A from equine rhinitis A virus, and F2A from foot and mouth disease virus. Among them, P2A has the highest cleavage efficiency and is therefore preferred. Various functional variants of these 2A polypeptides are also known in the art and can be used in the present invention.

[0118] In some embodiments, the polynucleotide comprises a nucleotide sequence that encodes the amino acid sequence represented by SEQ ID NO:58.

[0119] In another aspect, the invention provides an expression vector comprising a polynucleotide of the invention operably linked to a control sequence.

[0120] An "expression vector" of the present invention can be a linear nucleic acid fragment, a circular plasmid, a viral vector, or a translatable RNA (e.g., mRNA). In some preferred embodiments, the expression vector is a viral vector, such as a lentiviral vector.

[0121] The terms "control sequence" and "control element" are used interchangeably and refer to nucleotide sequences located upstream (5' non-coding sequences), in the middle, or downstream (3' non-coding sequences) of a coding sequence and that influence the transcription, RNA processing, or stability, or translation of the associated coding sequence. Expression control elements refer to nucleotide sequences that can control the transcription, RNA processing, or stability, or translation of a nucleotide sequence of interest. Control sequences can include, but are not limited to, promoters, translation leader sequences, introns, enhancers, and polyadenylation recognition sequences.

[0122] As used herein, the term "operably linked" means that a control element (e.g., but not limited to, a promoter sequence, a transcription termination sequence, etc.) is linked to a nucleic acid sequence (e.g., a coding sequence or an open reading frame) such that transcription of the nucleotide sequence is controlled and is controlled by the transcriptional control element. Techniques for operably linking a control element region to a nucleic acid molecule are known in the art.

[0123] In another aspect, the invention provides a method for preparing a therapeutic immune cell of the invention, the method comprising the step of introducing a polynucleotide or expression vector of the invention into the immune cell.

[0124] The immune cells of the present invention, such as T cells or NK cells, can be obtained by a variety of non-limiting methods from many sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, ascites, pleural effusion, spleen tissue, and tumors. In some embodiments, the cells can be derived from a healthy donor or a patient diagnosed with cancer. In some embodiments, the cells can be part of a mixed population of cells that exhibit different phenotypic profiles. For example, T cells can be obtained by isolating peripheral blood mononuclear cells (PBMCs), then activating and amplifying them with a specific antibody.

[0125] In some embodiments of aspects of the invention, the immune cells, such as T cells, are derived from the subject's autologous cells. As used herein, "autologous" means that the cells, cell line, or cell population used to treat the subject are derived from the subject. In some embodiments, the immune cells, such as T cells, are derived from allogeneic cells, such as from a donor that is human leukocyte antigen (HLA) compatible with the subject. Cells from the donor can be converted to non-allo-reactive cells using standard protocols and replicated as needed to generate cells that can be administered to one or more patients.

[0126] In another aspect, the invention provides a pharmaceutical composition comprising the therapeutic immune cells of the invention and a pharma- ceutically acceptable carrier.

[0127] As used herein, "pharmaceutically acceptable carrier" includes any and all physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption inhibitors, etc. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion).

[0128] In another aspect, the invention provides the use of the therapeutic immune cells of the invention in the preparation of a medicament for treating a disease in a subject.

[0129] As used herein, "subject" refers to an organism suffering from or susceptible to a disease (e.g., cancer) treatable by the cells, methods, or pharmaceutical compositions of the present invention. Non-limiting examples include humans, cattle, rats, mice, dogs, monkeys, goats, sheep, cows, deer, and other non-mammals. In some preferred embodiments, the subject is a human.

[0130] In another aspect, the invention provides a method for treating a disease, such as cancer, in a subject, the method comprising the step of administering to the subject an effective amount of a therapeutic immune cell or pharmaceutical composition of the invention.

[0131] As used herein, a "therapeutically effective amount" or a "therapeutically effective dose" or an "effective amount" refers to an amount of a substance, compound, material, or cell that is sufficient to produce at least a therapeutic effect after administration to a subject. Such an amount is thus the amount necessary to prevent, remedy, ameliorate, block, or partially block the symptoms of a disease or disorder. For example, an "effective amount" of the cells or pharmaceutical composition of the present invention may preferably cause a decrease in the severity of the symptoms of the disorder, an increase in the frequency and duration of asymptomatic periods of the disorder, or prevention of injury or disability as a result of suffering from the disorder. For example, when treating a tumor, an "effective amount" of the cells or pharmaceutical composition of the present invention may preferably inhibit tumor cell proliferation or tumor growth by at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40%, more preferably at least about 50%, more preferably at least about 60%, more preferably at least about 70%, and more preferably at least about 80% compared to an untreated subject. The ability to inhibit tumor growth can be assessed in an animal model system that may be predictive of efficacy in human tumors. Alternatively, the evaluation can be carried out by examining the inhibitory ability on the proliferation of tumor cells, which can be determined in vitro by tests known to those skilled in the art.

[0132] In practice, the dosage level of the cells in the pharmaceutical composition of the present invention may be varied to obtain an amount of active ingredient that can effectively achieve the desired therapeutic response for a particular patient, a composition and route of administration that is not toxic to the patient. The selected dosage level will depend on various pharmacokinetic factors, including the activity of the specific composition of the present invention applied, the route of administration, the time of administration, the rate of excretion of the specific compound applied, the duration of treatment, other drugs, compounds, and / or materials applied in combination with the specific composition applied, the age, sex, weight, condition, general health, and medical history of the patient being treated, and similar factors known in the medical art.

[0133] Administration of the therapeutic immune cells or pharmaceutical compositions or drugs according to the invention can be carried out in any convenient manner, such as through injection, infusion, implantation, or transplantation. Administration of the cells or compositions described herein can be intravenous, intralymphatic, intradermal, intratumoral, intramedullary, intramuscular, or intraperitoneal. In one embodiment, the cells or compositions of the invention are preferably administered by intravenous injection.

[0134] In embodiments of the various aspects of the invention, the disease is a CD19 and / or CD20 associated disease, such as a disease associated with aberrant expression of CD19 and / or CD20, such as a CD19 and / or CD20 associated cancer. The cancer can be a B cell malignancy, such as a chronic or acute leukemia (including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia), lymphocytic lymphoma, non-Hodgkin's lymphoma, and the like, and combinations thereof. In some embodiments, the cancer is a CD19 and / or CD20 positive cancer. Further embodiments are as follows. [Embodiment 1] i) an αβ TCR comprising a T cell receptor (TCR) α chain and a TCR β chain, wherein at least one functional domain is linked to the C-terminus of the TCR α chain and / or the TCR β chain of the αβ TCR; the TCR α chain comprises a first constant region and a first antigen-binding region, and the TCR β chain comprises a second constant region and a second antigen-binding region; an αβ TCR, wherein the first antigen-binding region specifically binds to a first antigen and the second antigen-binding region specifically binds to a second antigen, or the first antigen-binding region and the second antigen-binding region in combination with each other specifically bind to the first antigen and the second antigen; Or, ii) a γδ TCR comprising a TCR γ chain and a TCR δ chain, wherein at least one functional domain is linked to the C-terminus of the TCR γ chain and / or the TCR δ chain of the γδ TCR; the TCR γ chain comprises a first constant region and a first antigen-binding region, and the TCR δ chain comprises a second constant region and a second antigen-binding region; the first antigen-binding region specifically binds to a first antigen and the second antigen-binding region specifically binds to a second antigen, or the first antigen-binding region and the second antigen-binding region in combination with each other specifically bind to the first antigen and the second antigen; Preferably, said first antigen is CD19 and said second antigen is CD20, or said first antigen is CD20 and said second antigen is CD19. A modified T cell receptor. [Embodiment 2] The modified T cell receptor of embodiment 1, wherein the antigen-binding region is derived from an antibody. [Embodiment 3] 3. The modified T cell receptor of embodiment 1 or 2, wherein i) the native endodomains of the TCR α and / or TCR β chain of the αβ TCR are deleted, or ii) the native endodomains of the TCR γ and / or TCR δ chain of the γδ TCR are deleted. [Embodiment 4] 4. The modified T cell receptor of embodiment 3, wherein in i) the αβ TCR, the functional domain is linked directly or via a linker to the C-terminus of the TCR α chain and / or the TCR β chain which is devoid of a native endodomain, or in ii) the γδ TCR, the functional domain is linked directly or via a linker to the C-terminus of the TCR γ chain and / or the TCR δ chain which is devoid of a native endodomain. [Embodiment 5] The linker is (G 4 S) n, wherein n represents an integer of 1 to 10, and preferably is 3. [Embodiment 6] at least one functional domain, such as an endodomain of a costimulatory molecule, is linked to the C-terminus of only one of the TCR α and TCR β chains of said αβ TCR of i), or 6. The modified T cell receptor of any one of embodiments 1 to 5, wherein at least one functional domain is linked to the C-terminus of only one of the TCR γ and TCR δ chains of said γδ TCR of ii). [Embodiment 7] The modified T cell receptor of embodiment 6, wherein at least one functional domain is linked to the C-terminus of the TCR α chain of said αβ TCR of i). [Embodiment 8] 8. The modified T cell receptor of embodiment 7, wherein the native endodomain of the TCR alpha chain is deleted. [Embodiment 9] The modified T cell receptor of embodiment 8, wherein the functional domain is linked directly or via a linker to the C-terminus of the TCR alpha chain lacking the native endodomain. [Embodiment 10] The linker may be, for example, (G 4 S) n, wherein n represents an integer from 1 to 10, and preferably, n is 3. [Embodiment 11] The modified T cell receptor of embodiment 6, wherein at least one functional domain is linked to the C-terminus of the TCR β chain of said αβ TCR of i). [Embodiment 12] 12. The modified T cell receptor of embodiment 11, wherein the native endodomain of the TCR β chain is deleted. [Embodiment 13] The modified T cell receptor of embodiment 12, wherein the functional domain is linked directly or via a linker to the C-terminus of the TCR β chain lacking the native endodomain. [Embodiment 14] The linker may be, for example, (G 4 S) n, wherein n represents an integer from 1 to 10, preferably n is 3. [Embodiment 15] The modified T cell receptor of embodiment 6, wherein at least one functional domain is linked to the C-terminus of the TCR gamma chain of said gamma delta TCR of ii). [Embodiment 16] 16. The modified T cell receptor of embodiment 15, wherein the native endodomain of the TCR gamma chain is deleted. [Embodiment 17] The modified T cell receptor of embodiment 16, wherein the functional domain is linked directly or via a linker to the C-terminus of the TCR gamma chain lacking the native endodomain. [Embodiment 18] The linker may be, for example, (G 4 S) n, wherein n represents an integer from 1 to 10, preferably n is 3. [Embodiment 19] The modified T cell receptor of embodiment 6, wherein at least one functional domain is linked to the C-terminus of the TCR δ chain of said γδ TCR of ii). [Embodiment 20] 20. The modified T cell receptor of embodiment 19, wherein the native endodomain of the TCR δ chain is deleted. [Embodiment 21] The modified T cell receptor of embodiment 20, wherein the functional domain is linked directly or via a linker to the C-terminus of the TCR δ chain lacking the native endodomain. [Embodiment 22] The linker may be, for example, (G 4 S) n, where n represents an integer from 1 to 10, preferably, n is 3. [Embodiment 23] 6. The modified T cell receptor of any one of embodiments 1 to 5, wherein at least one functional domain is linked to the C-terminus of each of the TCR α chain and TCR β chain of the αβ TCR of i). [Embodiment 24] 24. The modified T cell receptor of embodiment 23, wherein the native endodomains of both the TCR alpha chain and the TCR beta chain are deleted. [Embodiment 25] The modified T cell receptor of embodiment 24, wherein the functional domains are linked directly or via a linker to the C-terminus of the TCR alpha chain and the TCR beta chain, each of which lacks a native endodomain. [Embodiment 26] The linker may be, for example, (G 4 S) n, wherein n represents an integer from 1 to 10, preferably n is 3. [Embodiment 27] 6. The modified T cell receptor of any one of embodiments 1 to 5, wherein at least one functional domain is linked to the C-terminus of each of the TCR γ and TCR δ chains of said γδ TCR of ii). [Embodiment 28] 28. The modified T cell receptor of embodiment 27, wherein the native endodomains of both the TCR gamma chain and the TCR delta chain are deleted. [Embodiment 29] The modified T cell receptor of embodiment 28, wherein the functional domain is linked directly or via a linker to the C-terminus of the TCR gamma chain and the TCR delta chain, each of which lacks a native endodomain. [Embodiment 30] The linker may be, for example, (G 4 S) n, wherein n represents an integer from 1 to 10, preferably n is 3. [Embodiment 31] 6. The modified T cell receptor of any one of embodiments 1 to 5, wherein the TCR α and TCR β chains of the αβ TCR in i) are linked to the same or different functional domains, or the TCR γ and TCR δ chains of the γδ TCR in ii) are linked to the same or different functional domains. [Embodiment 32] 32. The modified T cell receptor of any one of embodiments 1-31, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more functional domains are linked to the C-terminus of the TCR α chain and / or TCR β chain of the αβ TCR in i) or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more functional domains are linked to the C-terminus of the TCR γ chain and / or TCR δ chain of the γδ TCR in ii). [Embodiment 33] 33. The modified T cell receptor according to any one of embodiments 1 to 32, wherein the at least one functional domain is selected from the endodomains of costimulatory molecules, such as CD40, OX40, ICOS, CD28, 4-1BB, CD27, and CD137, or co-inhibitory molecules, such as TIM3, PD1, CTLA4, and LAG3, or the endodomains of cytokine receptors, such as interleukin receptors (such as IL-2 receptor), interferon receptors, tumor necrosis factor superfamily receptors, colony stimulating factor receptors, chemokine receptors, growth factor receptors, or other membrane proteins, or domains of intracellular proteins, such as NIK. [Embodiment 34] 34. The modified T cell receptor of any one of embodiments 1 to 33, wherein the endodomain of the costimulatory molecule is OX40 or ICOS, preferably OX40. [Embodiment 35] 35. The modified T cell receptor of any one of embodiments 1 to 34, wherein the first constant region is a native TCR alpha chain constant region, such as a native human TCR alpha chain constant region or a native mouse TCR alpha chain constant region, or the first constant region is a native TCR gamma chain constant region, such as a native human TCR gamma chain constant region or a native mouse TCR gamma chain constant region. [Embodiment 36] 35. The modified T cell receptor of any one of embodiments 1 to 34, wherein the first constant region is a modified TCR alpha chain constant region or a modified TCR gamma chain constant region. [Embodiment 37] The modified T cell receptor of embodiment 36, wherein the modified TCR alpha chain constant region is derived from a mouse TCR alpha chain constant region in which the amino acid at position 48, such as threonine (T), has been mutated to cysteine ​​(C) compared to the wild-type mouse TCR alpha chain constant region. [Embodiment 38] The modified T cell receptor of embodiment 36, wherein the modified TCR alpha chain constant region is derived from a mouse TCR alpha chain constant region in which, compared to the wild-type mouse TCR alpha chain constant region, the amino acid at position 112, such as serine (S), is mutated to leucine (L), the amino acid at position 114, such as methionine (M), is mutated to isoleucine I, and the amino acid at position 115, such as glycine (G), is mutated to valine (V). [Embodiment 39] The modified T cell receptor according to embodiment 36, wherein the modified TCR α chain constant region is derived from a mouse TCR α chain constant region in which, compared to the wild-type mouse TCR α chain constant region, amino acids such as E at position 6 are replaced with D, K at position 13 is replaced with R, and amino acids at positions 15 to 18 are deleted. [Embodiment 40] 37. The modified T cell receptor of embodiment 36, wherein the modified TCR alpha chain constant region is derived from a mouse TCR alpha chain constant region in which, compared to the wild-type mouse TCR alpha chain constant region, the amino acid at position 48, such as threonine (T), is mutated to cysteine ​​(C), the amino acid at position 112, such as serine (S), is mutated to leucine (L), the amino acid at position 114, such as methionine (M), is mutated to isoleucine (I), and the amino acid at position 115, such as glycine (G), is mutated to valine (V). [Embodiment 41] 37. The modified T cell receptor according to embodiment 36, wherein the modified TCR α chain constant region is derived from a mouse TCR α chain constant region in which, compared to a wild-type mouse TCR α chain constant region, an amino acid, such as E at position 6, has been substituted with D, K at position 13 has been substituted with R, amino acids at positions 15 to 18 have been deleted, the amino acid at position 48, such as threonine (T), has been mutated to cysteine ​​(C), the amino acid at position 112, such as serine (S), has been mutated to leucine (L), the amino acid at position 114, such as methionine (M), has been mutated to isoleucine (I), and the amino acid at position 115, such as glycine (G), has been mutated to valine (V). [Embodiment 42] The modified T cell receptor of any one of embodiments 1 to 34, wherein the first constant region comprises an amino acid sequence represented by one of SEQ ID NOs: 1, 3, 5, 7, 8, 26, 41, 42, and 48. [Embodiment 43] 43. The modified T cell receptor of any one of embodiments 1 to 42, wherein the second constant region is a native TCR β chain constant region, such as a native human TCR β chain constant region or a native mouse TCR β chain constant region, or the second constant region is a native TCR δ chain constant region, such as a native human TCR δ chain constant region or a native mouse TCR δ chain constant region. [Embodiment 44] 43. The modified T cell receptor of any one of embodiments 1 to 42, wherein the second constant region is a modified TCR β chain constant region or a modified TCR δ chain constant region. [Embodiment 45] The modified T cell receptor of embodiment 44, wherein the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which the amino acid at position 56, such as serine (S), has been mutated to cysteine ​​(C) compared to the wild-type mouse TCR β chain constant region. [Embodiment 46] The modified T cell receptor according to embodiment 45, wherein the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which, compared to a wild-type mouse TCR β chain constant region, the amino acid at position 3, e.g., R, is replaced with K, the amino acid at position 6, e.g., T, is replaced with F, K at position 9 is replaced with E, S at position 11 is replaced with A, L at position 12 is replaced with V, and amino acids at positions 17 and 21 to 25 are deleted. [Embodiment 47] The modified T cell receptor according to embodiment 44, wherein the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which, compared to a wild-type mouse TCR β chain constant region, the amino acid at position 56, such as serine (S), is mutated to cysteine ​​(C), the amino acid at position 3, such as R, is substituted with K, the amino acid at position 6, such as T, is substituted with F, K at position 9 is substituted with E, S at position 11 is substituted with A, L at position 12 is substituted with V, and amino acids at positions 17 and 21 to 25 are deleted. [Embodiment 48] 43. A modified T cell receptor according to any one of embodiments 1 to 42, comprising an amino acid sequence represented by one of SEQ ID NOs: 2, 4, 6, 9, 27, 43, and 49. [Embodiment 49] 49. The modified T cell receptor of any one of embodiments 1 to 48, wherein the antigen-binding region is derived from an antibody. [Embodiment 50] the antigen-binding region comprises a single chain antibody or a single domain antibody; For example, the single chain antibody may be a single chain antibody, wherein n is an integer of 1 to 10, and preferably n is 1 or 3 (G 4 50. The modified T cell receptor of any one of embodiments 1 to 49, comprising a heavy chain variable region and a light chain variable region linked by a linker, such as a linker such as S)n. [Embodiment 51] 51. The modified T cell receptor of any one of embodiments 1 to 50, wherein the antigen-binding region that specifically binds to CD19 comprises a heavy chain variable region amino acid sequence represented by SEQ ID NO: 44 and a light chain variable region amino acid sequence represented by SEQ ID NO: 45. [Embodiment 52] 51. The modified T cell receptor of any one of embodiments 1 to 50, wherein the antigen-binding region that specifically binds to CD19 comprises a heavy chain variable region amino acid sequence represented by SEQ ID NO: 46 and a light chain variable region amino acid sequence represented by SEQ ID NO: 47. [Embodiment 53] 51. The modified T cell receptor of any one of embodiments 1 to 50, wherein the antigen-binding region that specifically binds to CD19 comprises the scFv amino acid sequence represented by SEQ ID NO:39. [Embodiment 54] 54. The modified T cell receptor of any one of embodiments 1 to 53, wherein the antigen-binding region that specifically binds to CD20 comprises a heavy chain variable region amino acid sequence represented by SEQ ID NO: 54 and a light chain variable region amino acid sequence represented by SEQ ID NO: 55. [Embodiment 55] 54. The modified T cell receptor of any one of embodiments 1 to 53, wherein the antigen-binding region that specifically binds to CD20 comprises a heavy chain variable region amino acid sequence represented by SEQ ID NO: 56 and a light chain variable region amino acid sequence represented by SEQ ID NO: 57. [Embodiment 56] 54. The modified T cell receptor of any one of embodiments 1 to 53, wherein the antigen-binding region that specifically binds to CD20 comprises the scFv amino acid sequence represented by SEQ ID NO:38. [Embodiment 57] The modified T cell receptor of embodiment 1, wherein the TCR alpha chain comprises the amino acid sequence represented by SEQ ID NO:59 and the TCR beta chain comprises the amino acid sequence represented by SEQ ID NO:60. [Embodiment 58] i) the first antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, while the second antigen-binding region comprises an antibody light chain variable region that specifically binds to the first antigen and an antibody light chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region combine with each other to specifically bind to both the first antigen and the second antigen; or ii) the first antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody light chain variable region that specifically binds to the second antigen, while the second antigen-binding region comprises an antibody light chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region combine with each other to specifically bind to both the first antigen and the second antigen; or iii) the first antigen-binding region comprises an antibody light chain variable region that specifically binds to the first antigen and an antibody light chain variable region that specifically binds to the second antigen, while the second antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region are combined with each other to specifically bind to both the first antigen and the second antigen; Preferably, the first antigen is CD19 and the second antigen is CD20, or the first antigen is CD20 and the second antigen is CD19. 50. A modified T cell receptor according to any one of embodiments 1 to 49. [Embodiment 59] An isolated therapeutic immune cell comprising a modified T cell receptor according to any one of embodiments 1 to 58. [Embodiment 60] 60. The therapeutic immune cell of embodiment 59, which is a T cell or a NK cell. [Embodiment 61] 61. A pharmaceutical composition comprising the therapeutic immune cells of embodiment 59 or 60 and a pharma- ceutically acceptable carrier. [Embodiment 62] Use of a therapeutic immune cell according to embodiment 59 or 60, or a pharmaceutical composition according to embodiment 61, in the preparation of a medicament for treating a disease, such as cancer, in a subject. EXAMPLES

[0135] Example 1: Improvement of STAR 1. Design of wild-type T cell receptors and STAR molecules with mutated constant regions 1.1 STAR Prototype Design Secretory antibodies (Ab) or B cell receptors (BCRs) produced by B cells have great similarity to T cell receptors (TCRs) in terms of gene structure, protein structure and spatial conformation. Both antibodies and TCRs consist of variable and constant regions, where the variable regions are responsible for antigen recognition and binding, while the constant domains are responsible for structural interactions and signal transduction. By replacing the variable regions of TCR α and β chains (or TCR γ and δ chains) with the heavy chain variable region (VH) and light chain variable region (VL) of an antibody, an artificial synthetic chimeric molecule called synthetic T cell receptor and antibody receptor (STAR / WT-STAR) can be constructed, the structure of which is shown in Figure 1 (left).

[0136] A STAR molecule has two chains, the first obtained by fusing an antigen recognition sequence (e.g. an antibody heavy chain variable region) with the constant region (Cα) of the T cell receptor alpha chain (TCRα) and the second obtained by fusing an antigen recognition sequence (e.g. an antibody light chain variable region) with the constant region (Cβ) of the T cell receptor beta chain (TCRβ). By positioning and combining the antigen recognition domains (e.g. VH, VL or scFv) and the constant domains (constant domains of TCR alpha, beta, gamma and delta) in the constructs, a variety of constructs can be formed with different configurations but similar functions.

[0137] After expression in T cells, the first and second chains of the STAR molecule combine with endogenous CD3εδ, CD3γε and CD3ζ chains in the endoplasmic reticulum to form an eight-subunit complex that is present on the surface of the cell membrane in the form of a complex. The immunoreceptor tyrosine-based activation motif (ITAM) is a signaling motif in TCR molecules with a conserved sequence of YxxL / V. The endodomains of CD3ε, δ, γ and ε chains contain one ITAM sequence, and the endodomain of CD3ζ chain contains three ITAM sequences, so the complete STAR complex has a total of 10 ITAM sequences. When the antigen recognition sequence of the STAR receptor binds to its specific antigen, the intracellular ITAM sequences are sequentially phosphorylated, which in turn activate downstream signaling pathways and activate transcription factors such as NF-κβ, NFAT and AP-1 to initiate T cell activation and generate effector functions. Previous studies by the present inventors have shown that STAR can activate T cells better than conventional chimeric antigen receptor CAR, and background activation in the absence of antigen stimulation is significantly reduced, thus STAR has significant advantages (see Chinese Patent Application No. 201810898720.2). However, further improvements to STAR are still desired.

[0138] 1.2. Mutant STARs (mut-STARs) and transmembrane- and endodomain-modified STARs (ub-STARs) The STAR prototype design uses humanized TCR α / β chain (or TCR γ and δ chain) constant region sequences (wild type human TCR α constant region, SEQ ID NO: 1; wild type human TCR β constant region, SEQ ID NO: 2). The constant region sequences of human, primate and mouse TCR α / β chains (mouse TCRaC-WT, SEQ ID NO: 3; mouse TCRbC-WT, SEQ ID NO: 4) are highly conserved and share the same key amino acid sequences, so these TCR α / β chains can be substituted for each other.

[0139] After being transferred into T cells, STAR molecules will mismatch with the endogenous TCR of T cells through the constant region. On the one hand, this mismatch problem may reduce the efficiency of correct pairing of STAR molecules, reducing the function of STAR molecules, but on the other hand, it may increase the possibility of unknown specificity caused by mismatch, increasing safety risk. To solve this problem, the inventors replaced the constant region of STAR molecules with mouse sequences, so as to enhance the function of STAR molecules after being transferred into human T cells. To further optimize the design of STAR molecules, the inventors performed cysteine ​​mutations into STAR molecules to introduce intermolecular disulfide bonds, thereby enhancing the mutual pairing between the two chains of STAR molecules and reducing the mismatch with endogenous TCR. Specifically, the threonine (T) at position 48 in the TCR α chain constant region was mutated to a cysteine ​​(C) (mouse TCRaC-Cys, SEQ ID NO: 5), and the serine (S) at position 56 in the TCR β chain constant region was mutated to a cysteine ​​(C) (mouse TCRbC-Cys, SEQ ID NO: 6). The two newly added cysteines will form disulfide bonds between the two chains of the STAR, which reduces the mismatch between the two chains of the STAR and the endogenous TCR chain, helping the STAR molecule to form a more stable complex, and thus function better. In addition, to further optimize the design of the STAR molecule, the inventors performed hydrophobic amino acid substitutions in the transmembrane domain of the STAR molecule to increase the stability of the STAR molecule and help the STAR molecule to perform a more sustained function. Specifically, three amino acid mutations were performed at amino acid positions 111-119 in the transmembrane domain of the TCR α chain constant region. Specifically, the serine (S) at position 112 was mutated to leucine (L), the methionine (M) at position 114 was mutated to isoleucine (I), and the glycine (G) at position 115 was mutated to serine (V). The entire amino acid sequence of this region was changed from LSVMGLRIL to LLVIVLRIL, this modification was designated mouse TCRaC-TM9, which generated the constant region sequence of SEQ ID NO:7.This design increases the hydrophobicity of the transmembrane domain, counteracting the instability caused by the positive charge carried by the TCR transmembrane domain and making the STAR molecule more stable on the cell membrane, thus resulting in better function. The structure of this design is shown in Figure 1 (middle).

[0140] After the TCR binds to an antigen and activation is complete, lysines in the endodomain and transmembrane domain of the TCR molecule are ubiquitinated by a series of ubiquitination reactions mediated by ubiquitin-activating enzymes, ubiquitin-conjugating enzymes and ubiquitin ligases, resulting in T cell endocytosis and endocytosis of the TCR molecule into the cell for further degradation by lysosomes, thereby decreasing the concentration of TCR molecules on the surface of the T cell membrane and resulting in a continuous decline in the effectiveness of T cell activation. We modified amino acids in the transmembrane domains or endodomains of the α and β chains in mut-STAR molecules, including mutating lysines to arginines in the α chain constant region endodomain and the β chain constant region transmembrane domain of the STAR molecules, generating the constant region sequences of mouse TCRα C-Arg mut (SEQ ID NO: 8) and mouse TCRβ C-Arg mut (SEQ ID NO: 9), respectively, to reduce endocytosis of STAR molecules caused by ubiquitination of lysines. This design reduces the possibility of ubiquitination of the transmembrane domains and endodomains of STAR molecules, thus reducing endocytosis of STAR molecules, allowing STAR molecules to become more stable on the cell membrane and obtain better function. The structure of this design is shown in Figure 1 (right).

[0141] 2. Design of wild-type STAR molecules and mutant STAR molecules containing costimulatory receptor endodomains To improve the in vivo proliferation capacity of mut-STAR cells, their effect on survival time and their ability to infiltrate into the tumor microenvironment and efficiently kill target cells, we engineered a new structure of the mut-STAR complex, and the enhanced mut-STAR cells can be tailored as needed to improve TCR-T clinical responses and achieve sustained curative effects.

[0142] 2.1. Design of mut-STAR molecules (co-STARs) containing costimulatory molecule receptor endodomains TCR is a special marker on the surface of all T cells, which can be divided into αβTCR and γδTCR, whose corresponding T cells are αβT cells and γδT cells, respectively. We have modified αβ-STAR and tγδ-STAR with costimulatory signals to improve the performance of αβT cells and γδT cells, respectively.

[0143] The TCR of αβT cells consists of the TCRα and TCRβ chains, which account for 90%-95% of all T cells. The αβTCR consists of a variable region and a constant region, where the variable region has a large diversity and is responsible for antigen recognition and binding, while the constant region domain is responsible for structural interactions and signal transduction. To enhance the toxicity and proliferation persistence of T cells, according to the present invention, a humanized costimulatory receptor endodomain sequence is introduced at the C-terminus of the αβ-STAR constant region (Figure 2) to study the effect on STAR T cell function. The STAR constant regions of the present invention include the unmodified WT-STAR constant region, the cys-STAR constant region containing an additional intramolecular disulfide bond, the murine hm-STAR constant region, and the mut-STAR with a combination of the three modifications described in subsection 1. The costimulatory signaling structures comprise the intracellular signaling domains of CD40, OX40, ICOS, CD28, 4-1BB or CD27, having the sequences of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, respectively. The costimulatory endodomain can be linked to the C-terminus of the TCR alpha or beta chain or both the TCR alpha and beta chains (co-STAR). Furthermore, a costimulatory endodomain can be linked directly or via a linker G4S / (G4S)n (the G4S linker sequences are SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, respectively) to the C-terminus of a TCR constant region or to the C-terminus of a TCR constant region lacking an endodomain sequence of a TCR molecule (endodomain-deleted TCR α chain constant region containing both cysteine ​​substitutions and hydrophobic region modifications (mouse TCRaC-del mut, SEQ ID NO:26), endodomain-deleted TCR β chain constant region containing cysteine ​​substitutions (mouse TCR βC-del mut, SEQ ID NO:27)) (co-linker-STAR, Figure 3).

[0144] The TCR of γδ T cells consists of TCRγ and TCRδ chains, and γδ T cells can be divided into three subgroups, γδ1, γδ2, and γδ3, based on the type of TCRδ chain, and different subgroups have different distribution in the human body. γδ T cells recognize antigens in an MHC-restricted manner, which plays an important role in pathogen and tumor surveillance. Experiments have shown that CD28 or 4-1BB and similar costimulatory signals play an important role in the activation and proliferation of γδ T cells. To improve the performance of γδ T cells, we introduced the endodomain sequence of human costimulatory molecule receptor into the C-terminus of TCRγ and TCRδ, respectively (Figure 2, right).

[0145] 2.2. Design of CD3 molecules containing costimulatory molecule receptor endodomains (co-CD3-STAR) CD3 subunits include γ, δ, ε and ζ chains and form a T cell receptor complex with TCR molecules that transmits signals from ectodomain to endodomain to regulate the state of the cell and respond to stimuli. To engineer enhanced TCR T cells and improve the in vivo tumor-killing, proliferation and survival time of T cells, we modified CD3 molecules by introducing human co-stimulatory molecule receptor endodomains at the C-terminus of CD3 γ (SEQ ID NO: 28), δ (SEQ ID NO: 29), ε (SEQ ID NO: 30) and ζ (SEQ ID NO: 31) chains ( FIG. 4 ). The modified CD3 molecules were expressed in mut-STAR T cells to improve their function.

[0146] 2.3. Design of CD3 molecules containing stimulatory domains of cytokine receptors (cytokine-STAR, CK-STAR) Cytokines play an important role in the proliferation, anti-tumor and differentiation of T cells. Different cytokines combine with their respective receptors to transmit signals from ectodomain to endodomain so that the cells can control their state and respond to stimuli. Furthermore, research has shown that the downstream molecule STAT5 (SEQ ID NO: 35) is activated by a cascade reaction in the IL-2 receptor endodomain, thereby enhancing the transcription of T cell proliferation-related molecules and enhancing the proliferation ability of CAR-T cells. To engineer enhanced STAR-T cells and improve the in vivo tumor-killing, proliferation and survival capacity of T cells, we modified STAR molecules by linking intracellular signalling domains of human cytokine receptors (e.g. IL-2β receptor endodomain IL2Rb, SEQ ID NO: 32; IL-7α receptor endodomain, SEQ ID NO: 33; IL-21 receptor endodomain, SEQ ID NO: 34, etc.) to the C-terminus of the TCR α or β chain or both α and β chains, or by further linking a STAT5 activating moiety to the IL-2β or IL-7Rα receptor endodomain via G4S (IL-2RbQ, SEQ ID NO: 36; IL-7RbQ, SEQ ID NO: 37) (Figure 5).

[0147] 3. Construction of vectors for wild-type STAR molecules and mutant STAR molecules containing costimulatory molecule receptor endodomains 3.1 Source of vectors The vectors used in the present invention, including viral vectors, plasmid vectors, etc., are purchased or synthesized from commercial companies, and the full length sequences of these vectors are available and the specific cleavage sites are known.

[0148] 3.2. Source of Fragments The TCR referred to in the present invention can be any functional TCR, including WT-STAR, mut-STAR, ub-STAR, co-STAR, co-linker-STAR, CK-STAR, co-CD3-STAR, etc., used in the present invention. Gene fragments, such as the variable region of TCR, the constant region of TCR, the endodomain of costimulatory molecule receptor, the intracellular signaling region of cytokine receptor, tag sequence, linker, etc., used in the present invention, were all synthesized by commercial companies. These gene fragments were linked by PCR.

[0149] In this example, optimization of the TCR complex was verified using STAR comprising ScFv as shown in SEQ ID NO: 38 (derived from OFA, an antibody targeting CD20) and / or ScFv as shown in SEQ ID NO: 39 (derived from FMC63, an antibody targeting CD19) and compared to Mock, a blank control group expressing only RFP protein (red fluorescent protein, RFP) as shown in SEQ ID NO: 40.

[0150] Vector construction The lentiviral vector used herein was pHAGE-EF1 α-IRES-RFP, in which the linear vector was obtained by restriction enzymes Not I / Nhe I, gene fragments were obtained by synthesis and PCR, and the complete vector was obtained by homologous recombination.

[0151] 4. Cell Line Construction 4.1 Construction of plasmid pHAGE-luciferase-GFP As a lentiviral vector, pHAGE can stably insert target genes into the genome of target cells, which is an important method for constructing stable cell lines. Luciferase is a kind of enzyme, which has catalytic activity that can catalyze the chemical autoluminescence of substrates, and can stably express luciferase in target cells and indicate the number of target cells after the addition of substrates, thus reflecting the effect of functional cells on target cells. The pHAGE-EF1A vector carrying restriction endonuclease NotI / ClaI cleavage sites was cleaved by the two enzymes, and the luciferase and GFP sequences were obtained by NCBI, and the fragment was synthesized by combining the luciferase gene with the GFP gene using overlap PCR by commercial company Ruiboxingke, and then the luciferase-GFP fragment was ligated into the pHAGE vector by homologous recombination.

[0152] 4.2 Construction of luciferase-carrying target cell lines After successfully constructing the lentivirus vector with luciferase and GFP, the lentivirus was packed by Lenti-X-293T, the lentivirus solution was concentrated by PEG8000, and the virus titer was measured by gradient dilution, then the lymphoma cell line Raji was infected, and 72 hours after infection, the presence of GFP-positive cells was observed by fluorescence microscope, and then the GFP-positive cells were sorted by flow sorter, and the monoclonal cells were selected for library construction and storage. At the same time, the luciferase substrate was used to incubate with target cells, and the expression and detection level of luciferase were detected to determine the expression level.

[0153] 4.3 Construction of TCRα-β knockout Jurkat cell line To construct the TCRα-β-Jurkat cell line, guide sequences were designed in the constant regions of the α and β chains based on the structural and sequence characteristics of the TCR. The exon sequences of the constant regions of the TCRα and β chains were obtained from NCBI, and the exon 1 sequences of the constant regions of the TCRα and β chains were submitted to the website tools.genome-engineering.org to design guide sequences. Based on the results, oligo sequences were synthesized, and then sgRNA-LentiCRISPR lentiviral vectors (purchased from Aidi gene) were constructed. The guide sequence of the α chain was linked to LentiCRISPR-puro, and the guide sequence of the β chain was linked to LentiCRISPR-BSD.

[0154] Packaging of sgRNA-LentiCRISPR lentivirus: HEK-293T were seeded in a 10 cm dish in advance, and when the cells grew to 80%-90%, the transfection system was added to the HEK-293T and the cells were returned to a 37°C incubator for culture. This time was designated as 0 hours, and fresh 10% FBS-DMEM was added 12 hours after transfection. Viruses were harvested 48 hours and 72 hours after transfection. The culture medium containing the virus was centrifuged and filtered, mixed with PEG8000, and placed at 4°C for more than 12 hours, then centrifuged at 3500 rpm for 30 minutes, the supernatant was discarded, and then resuspended and precipitated with an appropriate volume of medium. The resulting product was frozen at -80°C or used directly.

[0155] Infection and screening of Jurkat T cells and identification of monoclonal cell lines: Jurkat T cells were seeded in 12 or 24 well plates, and then α-chain and β-chain sgRNA-LentiCRISPR viruses were added simultaneously in appropriate volumes along with polybrene (added at a ratio of 1:1000 based on total volume) and mixed thoroughly. Centrifugal infection was performed at 1000 rpm, 32°C for 90 min. The result was placed in a 37°C incubator, which was designated as 0 h. The liquid was replaced after 10-12 h. After 48 h, puromycin and BSD were added to the appropriate final concentrations, and after another 48 h of treatment, all the cells in the uninfected control group were killed as indicated. The surviving cells were aspirated, centrifuged, and cultured in complete medium to obtain a TCRα-β-Jurkat cell bank. After 2 weeks of culture, single cells were sorted from the TCRα-β-Jurkat cell bank into 96-well plates using the Aria flow sorter, and the grown monoclones were aspirated for expansion culture. Monoclonal cell lines were identified using TCR α- and β-chain antibodies, respectively, and cell lines lacking both chains were expanded to obtain endogenous TCR knockout Jurkat-T cell lines.

[0156] 5. Construction of a viral packaging system for transducing T cells 5.1 Lentiviral systems and packaging methods (different generations) Lentix-293T cells were cultured in a 10 cm dish at 5 × 10 5The cells were inoculated at 1000μL / mL and cultured in a 37℃, 5% CO2 incubator, and transfection was performed when the cell density reached approximately 80% (observed under a microscope). The three plasmids were mixed with 500μL of serum-free DMEM in a PMD2.G:PSPAX:transfer plasmid ratio of 1:2:3. 54μL of PEI-Max and 500uL of serum-free DMEM were mixed evenly and left at room temperature for 5 minutes (3:1 volume-to-mass ratio of PEI-Max to plasmid). The PEI-max mixture was slowly added to the plasmid mixture, gently blown and mixed evenly, then left at room temperature for 15 minutes. The final mixture was slowly added to the culture medium, mixed evenly, then placed back in the incubator for further culture for 12-16 hours, then replaced with 6% FBS DMEM medium for further culture, and the virus solution was collected at 48 and 72 hours.

[0157] 5.2 Viral titration Jurkat-C5 cells were cultured in flat-bottom 96-well plates at 1.5 × 10 5 Cells / mL were inoculated, and 100uL of 1640 medium containing 10% FBS and 0.2μL of 1000x polybrene were added to each well. Virus dilutions were performed at 10-fold dilutions using 1640 complete medium, and the amount of virus in the first well was 100μL if determined as virus stock solution, or 1μL if determined as concentrated solution. Diluted cells were added to virus wells at 100μL / well, mixed at 32°C, centrifuged at 1500rpm for 90 minutes, and cultured for 72 hours in a 37°C, 5% CO2 incubator. Cells were aspirated from flat-bottom 96-well plates into round-bottom 96-well plates, centrifuged at 4°C and 1800rpm for 5 minutes, and the supernatant was discarded. 200μL of 1x PBS was added, followed by centrifugation at 4°C and 1800rpm for 5 minutes, and the supernatant was discarded. 200 uL of 4% tissue fixation solution was added, and the resulting solution was kept away from light and measured using flow cytometry. Infection efficiency was measured by flow cytometry and calculated using the formula: titer (TU / mL) = 1.5 x 10 4Wells with an infection rate of 2-30% were selected when the titer was calculated according to × positive rate / virus volume (μL) × 1000. Viruses of the following plasmids were packaged by the above method: pHAGE-EF1A-IRES-RFP, WT-STAR, mut-STAR, co-WT-STAR (αβ-4-1BB-WT, αβ-CD27-WT, αβ-CD28-WT, αβ-ICOS-WT, αβ-OX40-WT, αβ-OX40-WT), co-STAR (αβ-4-1BB, αβ-CD27, αβ-CD28, αβ-ICOS, αβ-OX40, αβ-OX40), co-CD3-STAR (CD3δ-4-1BB, CD3δ-CD28), co-CD3δ-CD28, ... , CD3δ-ICOS, CD3δ-OX40, CD3ε-4-1BB, CD3ε-CD28, CD3ε-ICOS, CD3ε-OX40, CD3γ-OX40, CD3γ-ICOS, CD3γ-OX40, CD3ζ-41BB, CD3ζ-CD28, CD3ζ-ICO S, CD3ζ-OX40), co-linker-STAR (TCRβ-del-OX40, TCRα-del-G4S-OX40, TCRα-del-G4S-OX40, TCRβ-del-(G4S)3-OX40, TCRβ-del-(G4S)7-OX40), C K-STAR (β-IL-2Rb STAR, β-IL-2RbQ STAR, α-IL-2RbQ STAR, α-IL-7RA STAR, α-IL-7RAQ STAR, α-IL-21R STAR), etc.

[0158] 6. Establishment of T cell culture and infection methods 6.1 Culture of Jurkat T cell line Jurkat T cell line was cultured at 3 × 10 5 / ml up to 3 × 10 6 The cells were cultured at a density of 100 / ml and passaged every 1-2 days. After cell counting, the required number of cells were taken, adjusted to the above density by supplementing the culture medium, and placed in a CO2 incubator for culture.

[0159] 6.2 Infection of Jurkat T cell line Count the cells and dilute to 1 x 10 6 / ml of cells were taken, centrifuged, replaced with liquid, resuspended with 1mL of RPMI1640 medium containing 10% FBS, added to a 24-well plate, and an appropriate amount of virus solution was added as well, centrifuged at 1500 rpm for 90 minutes, and placed in a CO2 incubator for culture. 12 hours after infection, the liquid was completely replaced with fresh RPMI1640 medium containing 10% FBS, and the positive rate was detected after 72 hours.

[0160] 6.3 Culture of primary human T cells Primary T cells were isolated by the Ficoil method and cultured at an initial density of 1 × 10 in X-VIVO medium containing 10% FBS and 100 IU / mL IL-2. 6 / mL and then added to well plates precoated with CD3- and RetroNectin r-fibronectin (final concentration of 5ug / ml each). The density of postmitotic cultures was 5×10 5 / mL up to 3 × 10 6 / mL and were passaged every 1 to 2 days.

[0161] 6.4 Infection of primary human T cells After 48 hours of culture, primary T cells were added with virus solution at MOI=20, centrifuged at 1500 rpm for 90 minutes, and then placed in a CO2 incubator for culture. After 24 hours of infection, X-VIVO medium containing 10% FBS and 100 IU / mL IL-2 was supplemented, the wells were rotated, and after 72 hours, the infection efficiency was detected by tag protein or antibody.

[0162] 6.5. Methods for detecting infection efficiency After 72 hours of infection, cells were uniformly aerated, counted, and diluted with 5 × 10 5 / ml was taken, centrifuged, and the supernatant was discarded. The staining solution used was PBS+2% FBS+2mM EDTA, and the corresponding antibody was added and incubated for 30 minutes, then PBS was added and washed twice, and detection was performed on the computer.

[0163] 7. In vitro functional assays for WT-STAR receptor and its mutant mut-STAR T cells 7.1. In Vitro Co-Culture Methods for T Cells and Target Cells Target cells, Raji-luciferase, Raji CD19KO - Luciferase, Raji CD20KO -Luciferase and primary T cells were suspension cells, and the corresponding number of cells were taken for co-incubation, mixed with target cell medium, centrifuged and cultured. The specific steps were as follows: primary T cells were infected with packaged and purified WT-STAR and mut-STAR T viruses, and the infection efficiency was detected by flow cytometry one day before co-culture, and the ratio of effector cells to target cells was determined, usually used in a 1:1 ratio, the total number of T cells was calculated according to the infection efficiency, and the usual amount of target cells used was 1 × 10 5 / well (96-well plate).

[0164] 7.2. Stimulation of T cells by target antigen The target antigen of the present invention is generally a cell surface protein, which can be used directly in T cell activation to detect T cell function. Positive T cells are usually counted at 1×10 5 100 μg / well, centrifuged, and activated for 24 hours, after which T cells or target cells were harvested to detect T cell function.

[0165] 7.3. Verification of T cell killing function: Luciferase assay T cells were co-cultured with target cells for 24 hours, then the cell suspension was gently and uniformly aerated, 150 μL of cell suspension was taken per well, added to a white 96-well plate, centrifuged at 1500 rpm / min for 5 minutes, the supernatant was taken, added with cell lysis solution to dissolve at room temperature for 15 minutes, then centrifuged at 4000 rpm / min for 15 minutes at 4°C, then two parallel wells were selected for each well to take the supernatant, added with luciferase substrate (firefly luciferase assay reagent), then detected by a multi-function microplate reader with a gain value fixed at 100 to obtain the chemiluminescence value. Calculation of cell killing: killing efficiency=100%-(effector cells-target cells value per well / control cells-target cells value per well).

[0166] 7.4. Luciferase assay T cell killing function test detection results showed that mutant mut-STAR T cells exhibited stronger T cell tumor killing ability, and mut-STAR T cell targets CD19 and CD20 expressed Raji-luciferase, Raji, as shown in Figure 6 and Table 1. CD19KO -Luciferase and Raji CD20KO After killing of -luciferase, the survival rates of the remaining tumors were 2.41%, 13.94% and 24.40%, respectively, which were significantly better than those of WT-STAR by 45.73%, 77.00% and 76.16%, indicating that the mutant mut-STAR had a more significant tumor-killing effect.

[0167] [Table 1]

[0168] 8. Effects of costimulatory endodomains linked to the C-terminus of both the TCR α and TCR β chains, or to the C-terminus of the TCR α or TCR β chain, on the function of STAR-T cells 8.1. In Vitro Co-Culture Methods for T Cells and Target Cells The target cells Raji-luciferase and primary T cells were suspension cells, and the corresponding number of cells were taken for co-incubation, mixed with target cell medium, centrifuged and cultured. The specific steps were as follows: primary T cells were infected with packaged and purified WT-STAR and mut-STAR T viruses, the infection efficiency was detected by flow cytometry one day before co-culture, the ratio of effector cells to target cells was determined, and the co-incubation was usually performed at a ratio of 8:1, 4:1, 2:1, 1:1, 1:2, 1:4 and 1:8, and the difference of co-incubation over time was also detected, usually at 6 hours, 12 hours, 24 hours, 36 hours and 48 hours. To detect the proliferation of co-STAR T cells, the target cells Raji-luciferase were incubated with primary T cells for 7 days to observe the changes in cell proliferation and IL-2 secretion, and then the positive T cells were selected by flow cytometry and subjected to static culture without antigen stimulation for 2 days, and then co-cultured with target cells again for 24 hours to detect killing by T cells. The usual amount of target cells used was 1 × 10 5 / well (96-well plate).

[0169] 8.2. Methods for stimulating T cells with target antigens The target antigen of the present invention was generally a cell surface protein, which can be used directly to activate T cells to detect T cell function, specifically, target antigen is usually administered at 1×10 5 The cells were added together with positive T cells (100 / well), centrifuged, and activated for 24 hours to collect cell suspensions or culture supernatants to detect T cell function, or activated for 6, 12, 24, 36, 48 hours, or 7 days to detect T cell killing function.

[0170] 8.3. Verification of T cell killing function: Luciferase assay T cells were co-cultured with target cells for different times, then the cell suspension was gently and uniformly aerated, 150μL of cell suspension per well was taken and added to a white 96-well plate, centrifuged at 1500rpm / min for 5 minutes, the supernatant was taken and added with cell lysis solution to dissolve at room temperature for 15 minutes, then centrifuged at 4℃ and 4000rpm / min for 15 minutes, then 2 parallel wells were selected for each well to take the supernatant and added with luciferase substrate (firefly luciferase assay reagent), then detected by a multi-function microplate reader with a gain value fixed at 100 to obtain the chemiluminescence value. Calculation of cell killing: killing efficiency=100%-(effector cells per well-target cells value / control cells per well-target cells value).

[0171] According to the detection results of the T cell killing function test by luciferase assay, as shown in Figure 7 and Table 2, mut-STAR with costimulatory endodomains linked to the C-terminus of both TCRα and TCRβ chains exhibited similar tumor killing effects at different E:T ratios of T cells and target cells, and there was no significant difference in the residual tumor survival rate at different E:T ratios. However, in terms of the detection results of tumor killing at different times, as shown in Figure 8 and Table 3, mut-STAR with OX40 endodomains linked to the C-terminus of both TCRα and TCRβ chains (αβ-OX40) and mut-STAR incubated with Raji-luciferase for 48 hours showed similar tumor killing effects of about 24% and 19%, respectively, which were significantly higher than other mut-STAR with costimulatory endodomains linked to the C-terminus of both TCRα and TCRβ chains (αβ-41BB, αβ-CD27, αβ-CD28, αβ-ICOS). The above results show that linking the endodomain of the costimulatory molecule OX40 to the C-terminus of both TCRα and TCRβ chains did not affect the killing effect of mut-STAR. Furthermore, the above results show that mut-STAR with the OX40 endodomain linked to the C-terminus of TCRα chain (α-OX40) or β chain (β-OX40) alone was detected by luciferase assay for T cell killing function, and the detection results showed that α-OX40 and β-OX40 showed no significant difference from α-β-OX40 at different E:T ratios of T cells to co-incubated tumor cells or 24 hours of co-incubation, as shown in Figures 9 and 10 and Tables 4 and 5. The above killing results showed that there was no significant difference between mut-STAR (αβ-OX40), in which the endodomain of the costimulatory molecule OX40 was linked to the C-terminus of both the TCR α chain and the TCR β chain, and mut-STAR, in which the endodomain of the costimulatory molecule OX40 was linked to the C-terminus of the TCR α chain (α-OX40) or β chain (β-OX40) alone, but their tumor-killing abilities were significantly better than that of mut-STAR.

[0172] 8.4. Analysis of cytokine secretion by T cells: ELISA During T cell activation, many cytokines, such as TNF-α, IFN-γ and IL-2, are released to help T cells kill target cells or promote the expansion of T cells themselves. After T cells are stimulated by target cells or antigens, the T cells are harvested, centrifuged, and the supernatant is taken. The TNF-α, IFN-γ, and IL-2 ELISA kits used were Human IL-2 Uncoated ELISA, Human TNF-α Uncoated ELISA, and Human IFN-γ Uncoated ELISA (item numbers 88-7025, 88-7346, and 88-7316, respectively). The specific steps were as follows: dilute 10X coating buffer with ddH2O to 1X, add coated antibody (250X), mix thoroughly, and add 100μL / well to a 96-well plate. After sealing with plastic wrap and leaving at 4℃ overnight, wash 3 times with 1X PBST (1X PBS with 0.05% Tween 20) at 260μL / well each time, dilute 5X ELISA / ELISPOT diluent to 1X with ddH2O, then add 200μL / well to 96-well plate, then leave at room temperature for 1 hour. Wash once with PBST, perform dilution according to standard curve (range 2-250, 4-500, 4-500, respectively), dilute samples 20-50 times with 1x diluent. Samples diluted according to the standard curve were added at 100 microliters per well, two parallel wells were selected, incubated at room temperature for 2 hours, washed 3 times with PBST, then detection antibody diluted in 1x diluent was added, after 1 hour incubation, washed 3 times with PBST, then HRP diluted in 1x diluent was added, after 30 minutes incubation, the solution was washed 6 times, TMB was added to develop the color with a development time of less than 15 minutes, 2N H2SO4 was added to stop, and the absorbance at 450 nm was detected.

[0173] According to the ELISA results, as shown in FIG. 11 and Table 6, after co-incubation of T cells with target cells for 24 hours, IL-2 secretion of mut-STAR (αβ-OX40), in which the OX40 endodomain is linked to the C-terminus of both the TCR α and TCR β chains, was about 10000pg / ml, which was significantly higher than that of STAR with other structures, and IL-2 secretion of mut-STAR, αβ-41BB, αβ-CD27, αβ-CD28 and αβ-ICOS was about 7700pg / ml, 6450pg / ml, 6690pg / ml, 6000pg / ml and 6050pg / ml, respectively. However, for TNFα and IFN-γ secretion, αβ-OX40 also showed similar results to mut-STAR, while the other structures showed different decreases. ELISA results showed that IL-2 secretion by mut-STAR (αβ-OX40), in which the endodomain of the costimulatory molecule OX40 is linked to the C-terminus of both the TCR α and TCR β chains, was significantly greater than that by mut-STAR.

[0174] 8.5. Detecting changes in T cell proliferation: Enumeration by flow cytometry During T cell activation, numerous cytokines are released to help T cells kill target cells or promote the expansion of T cells themselves, and the most obvious manifestation of T cell proliferation was the significant change in the number of T cells. T cells were incubated with target cells for 7 days, then centrifuged and resuspended with PBS to 200uL, and the number of positive T cells was counted by flow cytometry. Change in T cell proliferation: fold expansion = number of positive T cells after 7 days / initial number of positive T cells added.

[0175] After selection, mut-STAR-T cells with various structures were co-cultured with Raji-luciferase cells at an E:T ratio of 1:3, which was designated as day 0. Then, cells were harvested on days 1 and 7, respectively, and flow analysis was performed. Among them, the medium used was 1640 complete medium without IL-2, and the initial number of TCR T cells was 1 × 10 5The cells were incubated independently at each time point, and the remaining co-incubated samples were replaced with half the liquid the next day, and the target cells were replenished. The cells used in the flow analysis were stained with anti-human CD3 antibody in advance, and a fixed volume of cells was collected and recorded when the analysis was performed on the machine, and the number and percentage of T cells in the system were known by conversion. As shown in Figure 12 and Table 7, the proliferation fold curve of the absolute number of mut-STAR cells showed that mut-STAR (αβ-OX40), in which the OX40 endodomain was linked to the C-terminus of both the TCR α chain and the TCR β chain, showed better activation and proliferation after recognizing the target cell epitope, which was significantly higher than that of mut-STAR. The proliferation of mut-STAR in which the OX40 endodomain is linked to the C-terminus of the TCR α chain (α-OX40) or β chain (β-OX40) alone is shown in Figure 13 and Table 8. The T cell proliferation after 7 days of mut-STAR (α-OX40) in which the OX40 endodomain is linked to the C-terminus of the TCR α chain alone was 11.75 times, while the T cell proliferation of other structures such as mut-STAR, β-OX40 and αβ-OX40 was 2.755 times, 4.128 times and 6.744 times, respectively, so the proliferation effect of α-OX40 was significantly higher than that of other structures. Combining the above tumor killing results, ELISA results and T cell proliferation results, mut-STAR (α-OX40) in which the OX40 endodomain is linked to the C-terminus of the TCR α chain alone showed enhanced proliferation and tumor killing ability compared to other structures.

[0176] The above results show that the best proliferation effect was obtained by linking the costimulatory molecule OX40 to the TCR-α chain without affecting the killing effect of T cells. Therefore, according to the results of the killing effect of mu-STAR, in which the endodomains of different costimulatory molecules are linked to the TCRα chain, on target cells at different E:T ratios of T cells, the killing effect of mut-STAR linked to the endodomain of the costimulatory molecule OX40 was better than that of STAR linked to other costimulatory domains. At E:T ratios of 1:2 and 1:4, the effect of mut-STAR T cells linked to the endodomain of the costimulatory molecule OX40 (α-OX40) was similar to that of αβ-OX40, and better than that of mut-STAR T cells linked to other costimulatory molecules. The results are shown in Figure 14 and Table 9. The above killing results showed that the tumor killing and proliferation potency conferred by mut-STAR (α-OX40), in which the OX40 endodomain is linked to the TCR α chain, was significantly greater than that of mut-STAR.

[0177] [Table 2]

[0178] [Table 3]

[0179] [Table 4]

[0180] [Table 5]

[0181] [Table 6]

[0182] [Table 7]

[0183] [Table 8]

[0184] [Table 9]

[0185] 9. Effect of costimulatory structures linked to different CD3 chains (co-CD3-STAR) on the function of STAR T cells 9.1. In Vitro Co-Culture Methods for T Cells and Target Cells The target cells Raji-luciferase and primary T cells were suspension cells, and the corresponding number of cells were taken for co-incubation, mixed with target cell medium, centrifuged and cultured. The specific steps were as follows: primary T cells were infected with packaged and purified WT-STAR and mut-STAR T viruses, and the infection efficiency was detected by flow cytometry one day before co-culture to determine the ratio of effector cells to target cells, usually co-incubated at a ratio of 1:1 or 2:1, and the target cells Raji-luciferase and primary T cells were co-incubated for 7 days to observe the change in cell proliferation number. The total number of T cells was calculated based on the infection efficiency, and the overall usage of target cells was 1 × 10 5 / well (96-well plate).

[0186] 9.2. Stimulation of T cells by target antigen The target antigen of the present invention is generally a cell surface protein, which can be used directly in T cell activation to detect T cell function. Positive T cells are usually counted at 1×10 5 The cells were added at 100x / well, centrifuged, activated for 24 hours, and the cell suspension or culture supernatant was harvested to detect T cell function.

[0187] 9.3. Validation of T cell killing function: Luciferase assay T cells were co-cultured with target cells for different times, then the cell suspension was gently and uniformly aerated, 150μL of cell suspension per well was taken into a white 96-well plate, centrifuged at 1500rpm / min for 5 minutes, the supernatant was taken and added with cell lysis solution to dissolve at room temperature for 15 minutes, then centrifuged at 4℃ and 4000rpm / min for 15 minutes, then 2 parallel wells were selected for each well to take the supernatant and added with luciferase substrate (firefly luciferase assay reagent), then detected by a multi-function microplate reader with a gain value fixed at 100 to obtain the chemiluminescence value. Calculation of cell killing: killing efficiency=100%-(effector cells-target cells value per well / control cells-target cells value per well).

[0188] According to the detection results of the T cell killing function test by luciferase assay, as shown in Figure 15 and Table 10, when the costimulatory endodomain was linked to the C-terminus of CD3δ or CD3γ or CD3ε or CD3ζ chain and co-expressed with mut-STAR T, the results showed that at the E:T ratio of various T cells to target cells of 1:1, none of the co-CD3-STARs exhibited a better target cell killing effect than αβ-OX40, but CD3δ-OX40, CD3ζ-41BB, CD3ζ-CD28, CD3ζ-ICOS, CD3ζ-OX40 exhibited similar killing effects compared to mut-STAR, and their residual tumor survival rates were not significantly different at the E:T ratio of 1:1. The above results indicate that the tumor-killing effect of mut-STAR was not significantly improved by linking the costimulatory endodomain to the C-terminus of various CD3 chains, but the effect of mut-STAR in which the costimulatory endodomain was linked to the C-terminus of the CD3ζ chain was not significantly decreased.

[0189] 9.4. Detecting changes in T cell proliferation: Enumeration by flow cytometry During T cell activation, numerous cytokines are released to help T cells kill target cells or promote the expansion of T cells themselves, and the most obvious manifestation of T cell proliferation was the significant change in the number of T cells. T cells were incubated with target cells for 7 days, then centrifuged and resuspended with PBS to 200uL, and the number of positive T cells was counted by flow cytometry. Change in T cell proliferation: fold expansion = number of positive T cells after 7 days / initial number of positive T cells added.

[0190] After selection, mut-STAR-T cells with various structures were co-cultured with Raji-luciferase cells at an E:T ratio of 1:3, which was designated as day 0. Then, cells were harvested on days 1 and 7, respectively, and flow analysis was performed. Among them, the medium used was 1640 complete medium without IL-2, and the initial number of TCR T cells was 1 × 10 5 The cells were incubated separately at each time point, and the next day, the remaining co-incubated samples were replaced with half of the liquid and the target cells were replenished. The cells used in the flow analysis were stained with anti-human CD3 antibody in advance, and a fixed volume of cells was taken and recorded when the analysis was performed on the machine, and the number and percentage of T cells in the system were obtained by conversion. As shown in Figure 16 and Table 11, the proliferation fold curves of the absolute number of mut-STAR cells show that none of the co-CD3-STARs exhibited a better target cell killing effect compared to αβ-OX40-mut-STAR, but CD3ε-CD28, CD3δ-OX40, CD3ζ-CD28, CD3ζ-ICOS, CD3ζ-OX40, etc. exhibited similar proliferation effects. Taking together the results of killing detection by luciferase assay and T cell proliferation, constructs in which costimulatory endodomains were linked to the C-terminus of CD3δ or CD3γ or CD3ε or CD3ζ chains and co-expressed in mut-STAR T did not show better tumor killing and proliferation effects compared to αβ-OX40-mut-STAR T cells.

[0191] [Table 10]

[0192] [Table 11]

[0193] 10. Effect of costimulatory endodomains containing linker G4S linked to endodomain-deficient α or β constant regions on the function of STAR T cells 10.1. In Vitro Co-Culture Methods for T Cells and Target Cells The target cells Raji-luciferase and primary T cells were suspension cells, and the corresponding number of cells were taken for co-incubation, mixed with target cell medium, centrifuged and cultured. The specific steps were as follows: primary T cells were infected with packaged and purified WT-STAR and mut-STAR T viruses, and the infection efficiency was detected by flow cytometry one day before co-culture to determine the ratio of effector cells to target cells, usually co-incubated at a ratio of 1:1 or 2:1, and the target cells Raji-luciferase and primary T cells were co-incubated for 7 days to observe the change in cell proliferation number. The total number of T cells was calculated based on the infection efficiency, and the overall usage of target cells was 1 × 10 5 / well (96-well plate).

[0194] 10.2. Stimulation of T cells by target antigen The target antigen of the present invention was generally a cell surface protein, which can be used directly to activate T cells to detect T cell function, specifically, target antigen is usually administered at 1×10 5 The cells were added with positive T cells (100 / well), centrifuged, activated for 24 hours, and the cell suspension or culture supernatant was harvested to detect T cell function.

[0195] 10.3. Validation of T cell killing function: Luciferase assay T cells were co-cultured with target cells for different times, then the cell suspension was gently and uniformly aerated, 150μL of cell suspension per well was taken into a white 96-well plate, centrifuged at 1500rpm / min for 5 minutes, the supernatant was taken and added with cell lysis solution to dissolve at room temperature for 15 minutes, then centrifuged at 4℃ and 4000rpm / min for 15 minutes, then 2 parallel wells were selected for each well to take the supernatant and added with luciferase substrate (firefly luciferase assay reagent), then detected by a multi-function microplate reader with a gain value fixed at 100 to obtain the chemiluminescence value. Calculation of cell killing: killing efficiency=100%-(effector cells-target cells value per well / control cells-target cells value per well).

[0196] The results of the luciferase assay for the T cell killing function test showed that the costimulatory endodomains with different lengths of G4S linkers were linked to the endodomain-deficient α or β constant regions, but the results at an E:T ratio of T cells to target cells of 1:1 showed that the α-del-OX40, α-OX40, α-del-G4S-OX40, α-del-(G4S)3-OX40, and α -β-ox40 showed similar killing effects, which were greater than those of α-del-(G4S)7-OX40 and α-del-(G4S)10-OX40, and the longer the linker, the weaker the T cell killing effect; when the linker was attached to the β constant region endodomain, β-del-OX40, β-ox40, β-del-(G4S)3-OX40 and α-β-ox40 showed similar killing effects, and again, the longer the linker, the weaker the T cell killing effect. Linking to OX40 (α-del-OX40 or β-del-OX40) after removal of the constant region endodomain showed little difference in efficacy compared to linking without such removal, but after addition of linkers (the number of linkers was 3 or less), the efficacy of α-del-(G4S)1-3-OX40 or β-del-(G4S)1-3-OX40 was better than that of α-del-OX40 or β-del-OX40. Comparison between the efficacy of linking a linker to an α constant region endodomain and that of linking a linker to a β constant region endodomain showed that the efficacy of linking a linker to an α constant region endodomain was better than that of linking a linker to a β constant region endodomain. However, as shown in Figures 17 and 18 and Tables 12 and 13, there was no significant difference in the residual tumor survival rate at an E:T ratio of 2:1. The above results show that mut-STAR in which a costimulatory endodomain containing a G4S linker is linked to an endodomain-deficient α or β constant region does not affect the tumor-killing effect of mut-STAR, and the effect when linked to an α constant region endodomain was better than that when linked to a β constant region endodomain, but the tumor-killing effect was weaker with increasing linker length.

[0197] 10.4. Analysis of cytokine secretion by T cells: ELISA During T cell activation, many cytokines, such as TNF-α, IFN-γ and IL-2, are released to help T cells kill target cells or promote the expansion of T cells themselves. After T cells are stimulated by target cells or antigens, the T cells are harvested, centrifuged, and the supernatant is taken. The TNF-α, IFN-γ, and IL-2 ELISA kits used were Human IL-2 Uncoated ELISA, Human TNF-α Uncoated ELISA, and Human IFN-γ Uncoated ELISA (item numbers 88-7025, 88-7346, and 88-7316, respectively). The specific steps were as follows: dilute 10X coating buffer with ddH2O to 1X, add coated antibody (250X), mix thoroughly, and add 100μL / well to a 96-well plate. After sealing with plastic wrap and leaving at 4℃ overnight, wash 3 times with 1X PBST (also called wash buffer, 1X PBS with 0.05% Tween 20) at 260μL / well each time, 5X ELISA / ELISPOT diluent was diluted to 1X with ddH2O and then added to the 96-well plate at 200μL / well, then left at room temperature for 1 hour. Wash once with PBST, dilution was performed according to the standard curve (ranges of 2-250, 4-500, and 4-500, respectively), and samples were diluted 20-50 times with 1x diluent. Samples according to the standard curve were added at 100 microliters per well, two parallel wells were selected, incubated at room temperature for 2 hours, washed 3 times with PBST, then detection antibody diluted in 1x diluent was added, after 1 hour incubation, washed 3 times with PBST, then HRP diluted in 1x diluent was added, after 30 minutes incubation, the solution was washed 6 times, TMB was added to develop the color with a development time of less than 15 minutes, stopped by adding 2N H2SO4, and absorbance was detected at 450 nm.

[0198] According to the ELISA results, as shown in Figures 19 and 20 and Tables 14 and 15, after co-incubation of T cells with target cells for 24 hours, the IL-2 and IFN-γ secretion of mut-STAR with the structure of α-del-(G4S)7-OX40OX40 was significantly less than that of mut-STAR, while the IL-2 secretion of each of the other structures, β-del-OX40, α-del-OX40, α-del-G4S-OX40 and α-del-(G4S)3-OX40, was similar to that of mut-STAR, and only β-del-OX40 exhibited IFN-γ secretion similar to that of mut-STAR, while the IFN-γ secretion of the other structures exhibited different reductions. According to the ELISA results, in the constructs lacking the endodomain of the α or β constant region, the deletion of the endodomain of the α chain affected IFN-γ secretion but not IL-2 secretion, while the deletion of the endodomain of the β chain had no effect on IL-2 or IFN-γ secretion. At the same time, after the deletion of the endodomain of the α chain, a linker was used to link it to the OX40 endodomain, but in the case of a linker with a length of less than 7, this did not affect IL-2 secretion but reduced IFN-γ secretion.

[0199] 10.5. Detecting changes in T cell differentiation: flow cytometric analysis During T cell activation, numerous cytokines and other chemokines were released, and signals were transmitted into the nucleus through cytokine or chemokine receptors to control T cell differentiation. T cells differentiate from primitive T cells (naive) to central memory T cells (Tcm), effector memory T cells (Tem), and finally to effector T cells (Teff). However, the proliferation and persistence of T cells in vivo are influenced by the number of T cells differentiated into central memory T cells (Tcm) and effector memory T cells (Tem). Memory T cells can be classified into stem cell T cells, central memory T cells, and effector memory T cells. The differentiation ratio of central memory T cells affects the sustained killing effect of T cells in vivo. The ratio of primitive T cells to effector T cells affects the tumor killing effect and persistence of T cells in vivo. The expression of CD45RA and CCR7 on the surface of T cells was detected by flow cytometry, which can indicate the differentiation of T cells. T cells were incubated with target cells for 7 days, centrifuged, stained with anti-human-CD45RA-Percp-cy5.5 and anti-human-CCR7-APC flow antibodies for 30 min, centrifuged again, washed with PBS, fixed with 4% paraformaldehyde solution, and T cell differentiation was detected by flow cytometry.

[0200] According to the flow cytometry results, as shown in Figure 21 and Table 16, when the costimulatory endodomain containing G4S linker was linked to the construct lacking the endodomain of the α or β constant region, the resulting α-del-(G4S)3-OX40 showed significant differentiation of central memory T cells, while the construct in which OX40 was directly linked to the endodomain of the α (α-del-OX40) or β (β-del-OX40) constant region also promoted the differentiation of central memory T cells. At the same time, as shown in Figure 22 and Table 17, the number of effector T cells of mut-STAR T cells with various modified constructs was significantly lower than that of mut-STAR, but the percentage of each naive T cells was significantly higher than that of mut-STAR naive T cells (28.3%). The tumor killing results, ELISA results and flow cytometric detection of cell differentiation together show that mut-STAR lacking the α or β constant region endodomain and linked to the OX40 endodomain via a (G4S)3 linker can significantly improve the differentiation of memory populations of T cells without affecting tumor killing efficacy and IL-2 secretion.

[0201] [Table 12]

[0202] [Table 13]

[0203] [Table 14]

[0204] [Table 15]

[0205] [Table 16]

[0206] [Table 17]

[0207] 11. Effect of TCR endocytosis-associated lysine modification to arginine in the transmembrane domain or endodomain on the function of mutant STAR-T cells 11.1. In Vitro Co-Culture Methods for T Cells and Target Cells The target cells Raji-luciferase and primary T cells were suspension cells, and the corresponding number of cells were taken for co-incubation, mixed with target cell medium, centrifuged and cultured. The specific steps were as follows: primary T cells were infected with packaged and purified WT-STAR and mut-STAR T viruses, and the infection efficiency was detected by flow cytometry one day before co-culture to determine the ratio of effector cells to target cells, usually co-incubated at a ratio of 1:1 or 2:1, and the target cells Raji-luciferase and primary T cells were co-incubated for 7 days to observe the change in cell proliferation number. The total number of T cells was calculated based on the infection efficiency, and the overall usage of target cells was 1 × 10 5 / well (96-well plate).

[0208] 11.2. Stimulation of T cells by target antigen While the targets of the present invention were generally cell surface proteins, this can be used directly in the activation of T cells to detect T cell function, specifically, target antigens are typically administered at 1×10 5 The cells were added with positive T cells (100 / well), centrifuged, activated for 24 hours, and the cell suspension or culture supernatant was harvested to detect T cell function.

[0209] 11.3. Validation of T cell killing function: Luciferase assay T cells were co-cultured with target cells for different times, then the cell suspension was gently and uniformly aerated, 150μL of cell suspension per well was taken into a white 96-well plate, centrifuged at 1500rpm / min for 5 minutes, the supernatant was taken and added with cell lysis solution to dissolve at room temperature for 15 minutes, then centrifuged at 4℃ and 4000rpm / min for 15 minutes, then 2 parallel wells were selected for each well to take the supernatant and added with luciferase substrate (firefly luciferase assay reagent), then detected by a multi-function microplate reader with a gain value fixed at 100 to obtain the chemiluminescence value. Calculation of cell killing: killing efficiency=100%-(effector cells-target cells value per well / control cells-target cells value per well).

[0210] According to the detection results of the T cell killing function test by luciferase assay, as shown in Figure 23 and Table 18, the tumor cell killing effect of ub-STAR, a mut-STAR in which the TCR endocytosis-related lysine in the transmembrane domain or endodomain was modified to arginine, was significantly lower than that of mut-STAR T cells when the E:T ratio of T cells to target cells was 2:1 or 1:1.

[0211] 11.4. Analysis of cytokines secreted by T cells: ELISA During T cell activation, many cytokines, such as TNF-α, IFN-γ and IL-2, are released to help T cells kill target cells or promote the expansion of T cells themselves. After T cells are stimulated by target cells or antigens, the T cells are harvested, centrifuged, and the supernatant is taken. The IFN-γ and IL-2 ELISA kits used were Human IL-2 Uncoated ELISA, Human IFN-γ Uncoated ELISA (item numbers 88-7025, 88-7346, and 88-7316, respectively). The specific steps were as follows: dilute 10X coating buffer with ddH2O to 1X, add coated antibody (250X), mix thoroughly, and add 100μL / well to a 96-well plate. After sealing with plastic wrap and leaving at 4℃ overnight, wash 3 times with 1X PBST (also called wash buffer, 1X PBS with 0.05% Tween 20) at 260μL / well each time, 5X ELISA / ELISPOT diluent was diluted to 1X with ddH2O and then added to the 96-well plate at 200μL / well, then left at room temperature for 1 hour. Wash once with PBST, dilution was performed according to the standard curve (ranges of 2-250, 4-500, and 4-500, respectively), and samples were diluted 20-50 times with 1x diluent. Samples diluted according to the standard curve were added at 100 microliters per well, two parallel wells were selected, incubated at room temperature for 2 hours, washed 3 times with PBST, then detection antibody diluted in 1x diluent was added, after 1 hour incubation, washed 3 times with PBST, then HRP diluted in 1x diluent was added, after 30 minutes incubation, the solution was washed 6 times, TMB was added to develop the color with a development time of less than 15 minutes, 2N H2SO4 was added to stop, and the absorbance at 450 nm was detected.

[0212] According to the ELISA results, as shown in Figures 24 and 25 and Tables 19 and 20, ub-STAR, a mutated STAR in which TCR endocytosis-related lysines in the transmembrane domain or endodomain have been modified to arginine, was co-incubated with target cells for 24 hours at an E:T ratio of T cells to target cells of 2:1, 1:1 or 1:2, but the IL-2 and IFN-γ secretion by ub-STAR was significantly lower than that of mut-STAR T cells.

[0213] 11.5. Detecting changes in T cell differentiation: flow cytometric analysis During T cell activation, numerous cytokines and other chemokines were released, and signals were transmitted into the nucleus through cytokine or chemokine receptors to control T cell differentiation. The proliferation and persistence of T cells in vivo was influenced by the number of T cells that differentiated into memory T cells. Memory T cells can be classified into stem cell T cells, central memory T cells, and effector memory T cells. The expression of CD45RA and CCR7 on the surface of T cells was detected by flow cytometry, which can indicate the differentiation of T cells. T cells were incubated with target cells for 7 days, centrifuged, stained with anti-human-CD45RA-Percp-cy5.5 and anti-human-CCR7-APC flow antibodies for 30 minutes, centrifuged again, washed with PBS, fixed with 4% paraformaldehyde solution, and the differentiation of T cells was detected by flow cytometry.

[0214] According to the flow cytometry results, as shown in Figures 26 and 27 and Tables 21 and 22, no significant difference was found between mut-STAR and ub-STAR, a mut-STAR with TCR endocytosis-related lysine in the transmembrane domain or endodomain modified to arginine, in the differentiation of central memory T cells or in the ratio of naive T cells to effector T cells, indicating that the modification of TCR endocytosis-related lysine in the transmembrane domain or endodomain to arginine had no significant effect on the differentiation of mut-STAR T cells. Combining the tumor killing results, ELISA results and flow cytometry tests of cell differentiation, ub-STAR, a mut-STAR with TCR endocytosis-related lysine in the transmembrane domain or endodomain modified to arginine, did not have an effective promoting effect on mut-STAR modification.

[0215] [Table 18]

[0216] [Table 19]

[0217] [Table 20]

[0218] [Table 21]

[0219] [Table 22]

[0220] 12. Effects of mutant STARs with different cytokine receptor stimulatory domains linked to α or β constant region endodomains on the function of STAR T cells 12.1. In Vitro Co-Culture Methods for T Cells and Target Cells The target cells Raji-luciferase and primary T cells were suspension cells, and the corresponding number of cells were taken for co-incubation, mixed with target cell medium, and then centrifuged and cultured. The specific steps were as follows: primary T cells were infected with packaged and purified WT-STAR and mut-STAR T viruses, and the infection efficiency was detected by flow cytometry one day before co-culture to determine the ratio of effector cells to target cells, usually co-incubated at a ratio of 1:1 or 2:1, and the target cells Raji-luciferase and primary T cells were co-incubated for 7 days to observe the change in cell proliferation number. The total number of T cells was calculated based on the infection efficiency, and the overall usage of target cells was 1 × 10 5 / well (96-well plate).

[0221] 12.2. Stimulation of T cells by target antigen While the targets of the present invention were generally cell surface proteins, this can be used directly in the activation of T cells to detect T cell function, specifically, target antigens are typically administered at 1×10 5 The cells were added with positive T cells (100 / well), centrifuged, activated for 24 hours, and the cell suspension or culture supernatant was harvested to detect T cell function.

[0222] 12.3. Validation of T cell killing function: Luciferase assay T cells were co-cultured with target cells for different times, then the cell suspension was gently and uniformly aerated, 150μL of cell suspension per well was taken and added to a white 96-well plate, centrifuged at 1500rpm / min for 5 minutes, the supernatant was taken and added with cell lysis solution to dissolve at room temperature for 15 minutes, then centrifuged at 4℃ and 4000rpm / min for 15 minutes, then 2 parallel wells were selected for each well to take the supernatant and added with luciferase substrate (firefly luciferase assay reagent), then detected by a multi-function microplate reader with a gain value fixed at 100 to obtain the chemiluminescence value. Calculation of cell killing: killing efficiency=100%-(effector cells per well-target cells value / control cells per well-target cells value).

[0223] According to the detection results of the T cell killing function test by luciferase assay, as shown in Figure 28 and Table 23, when different cytokine receptor stimulatory domains were linked to the α or β domain endodomain of mutant STAR at an E:T ratio of T cells to target cells of 2:1, β-IL-2Rb, α-IL-2Rb, α-IL-7RA, and α-IL21R all exhibited killing effects similar to that of mut-STAR, while β-IL2RbQ, α-IL2RbQ, and α-IL7RAQ exhibited tumor killing effects significantly lower than that of mut-STAR. Furthermore, as shown in Figure 29 and Table 24, the killing effects of mutant STARs linked to different cytokine receptor stimulatory domains were detected at E:T ratios of 2:1 and 1:1 and compared with that of α-del-(G4S)3-OX40-STAR, and the killing effect of α-IL7RA was slightly lower than that of α-del-(G4S)3-OX40-STAR, while the killing effects of STARs linked to other cytokine receptor structures were significantly lower than that of α-del-(G4S)3-OX40-STAR.

[0224] 12.4. Analysis of cytokines secreted by T cells: ELISA During T cell activation, many cytokines, such as TNF-α, IFN-γ and IL-2, are released to help T cells kill target cells or promote the expansion of T cells themselves. After T cells are stimulated by target cells or antigens, the T cells are harvested, centrifuged, and the supernatant is taken. The IFN-γ and IL-2 ELISA kits were Human IL-2 Uncoated ELISA, Human IFN-γ Uncoated ELISA (item numbers 88-7025, 88-7346, and 88-7316, respectively). The specific steps were as follows: dilute 10X coating buffer with ddH2O to 1X, add coated antibody (250X), mix thoroughly, and add 100μL / well to 96-well plate. After sealing with plastic wrap and leaving at 4℃ overnight, wash 3 times with 1X PBST (also called wash buffer, 1X PBS with 0.05% Tween 20) at 260μL / well each time, 5X ELISA / ELISPOT diluent was diluted to 1X with ddH2O and then added to the 96-well plate at 200μL / well, then left at room temperature for 1 hour. Wash once with PBST, dilution was performed according to the standard curve (ranges of 2-250, 4-500, and 4-500, respectively), and samples were diluted 20-50 times with 1x diluent. Samples diluted according to the standard curve were added at 100 microliters per well, two parallel wells were selected, incubated at room temperature for 2 hours, washed 3 times with PBST, then detection antibody diluted in 1x diluent was added, after 1 hour incubation, washed 3 times with PBST, then HRP diluted in 1x diluent was added, after 30 minutes incubation, the solution was washed 6 times, TMB was added to develop the color with a development time of less than 15 minutes, 2N H2SO4 was added to stop, and the absorbance at 450 nm was detected.

[0225] According to the ELISA results, when T cells were incubated with target cells for 24 hours at an E:T ratio of 1:1 or 1:2, IL-2 secretion of β-IL-2Rb was significantly higher than that of mut-STAR, while α-IL-2Rb, β-IL-2RbQ and α-IL-7RAQ exhibited similar IL-2 secretion, but α-IL-2RbQ's IL-2 secretion was significantly lower than that of mut-STAR, as shown in Figure 30 and Table 25. IFN-γ secretion of β-IL-2Rb was significantly higher than that of mut-STAR, while IFN-γ secretion of the other constructs was significantly lower than that of mut-STAR, as shown in Figure 31 and Table 26.

[0226] 12.5. Detecting changes in T cell differentiation: flow cytometric analysis During T cell activation, numerous cytokines and other chemokines were released, and signals were transmitted into the nucleus through cytokine or chemokine receptors to control the changes in T cell differentiation. The proliferation and persistence of T cells in vivo was influenced by the number of T cells differentiated into memory T cells. Memory T cells can be classified into stem cell T cells, central memory T cells and effector memory T cells. The expression of CD45RA and CCR7 on the surface of T cells was detected by flow cytometry, which provided the status of T cell differentiation. T cells were incubated with target cells for 7 days, then centrifuged, stained with anti-human-CD45RA-Percp-cy5.5 and anti-human-CCR7-APC flow antibodies for 30 minutes, centrifuged again, washed with PBS, fixed with 4% paraformaldehyde solution, and T cell differentiation was detected by flow cytometry.

[0227] As shown in Figures 32 and 33 and Tables 27 and 28, mutant STARs with different cytokine receptor stimulatory regions linked to α or β constant region endodomains showed various changes in the differentiation of central memory T cells and the ratio of naive to effector T cells, with α-IL-2Rb, β-IL-2Rb, α-IL-2RbQ, β-IL-2RbQ showing no significant difference compared to mut-STAR, while α-IL-7RA, α-IL-7RAQ and α-IL-21R showing no significant difference compared to mut-STAR. From the above results, when different cytokine receptor stimulatory regions were linked to the α or β constant region endodomains of mutant STARs, the differentiation of mut STAR T cells was significantly affected.

[0228] [Table 23]

[0229] [Table 24]

[0230] [Table 25]

[0231] [Table 26]

[0232] [Table 27]

[0233] [Table 28]

[0234] 13. Evaluation of in vivo proliferation and antitumor capacity of various STAR-like T cells 1) Experimental Animal Models In this experiment, NSG immunodeficient mice were used as a model. The mouse genotype was NOD-Prkdcem26Il2rgem26 / Nju, and the mice lacked T cells, B cells, and NK cells, and the mice also lacked macrophages and dendritic cells. NSG mice are currently the most completely immunodeficient mouse strain, which does not reject transplanted tumors and T cells, and can therefore be widely used in preclinical research of T cell therapy. Female NSG mice aged 6 to 8 weeks were used in this experiment, and the weight difference between mice in each batch was controlled within 2 g. The mice were placed in separate ventilated cages within a specific pathogen-free (SPF) barrier and were given a normal diet and drinking water with a slightly acidic pH to prevent pathogen contamination.

[0235] 2) Construction of tumor models To establish a hematological tumor model, human Burkitt's lymphoma cell line Raji cells were used for xenograft transplantation. Raji cells are a cell line expressing luciferase gene by lentiviral vector, and the development and changes of Raji tumors in mice were monitored in real time by fluorescein chemiluminescence and in vivo imaging. In this model, different doses (approximately 1-3 × 10 6 Raji-luciferase cells (Raji cells) were mixed with matrix gel and inoculated into 6-8 week-old female NSG mice by intraperitoneal injection. Three days later, the mice were intraperitoneally injected with fluorescein potassium salt solution, and the fluorescent signals of the tumor cells in vivo were detected by in vivo imaging. Raji cells grew rapidly in the mice, producing solid tumors in the peritoneal cavity and causing symptoms, such as weight loss, in the mice. In the absence of therapeutic treatment, Raji tumor burden led to the death of the mice in about 40 days.

[0236] 3) Animal experiment procedures All animal procedures were performed following approval of the animal protocol.

[0237] 4) Means for monitoring tumor growth This experiment basically used in vivo fluorescence imaging by injecting tumor cells carrying luciferase gene into animals and allowing them to settle. Mice were intraperitoneally injected with fluorescein potassium salt solution, which in the presence of enzymes would emit light with a specific wavelength as a substrate, and the fluorescent signal of tumor cells in vivo was detected by in vivo imaging. Quantitative analysis of the fluorescent signal was performed, and a heat map was drawn to quantitatively reflect tumor growth.

[0238] 5) Methods for detecting T cell activity and expansion in animals The survival and expansion of T cells in vivo are directly related to the final antitumor effect of T cells. To detect the activity and proliferation of T cells in animals, blood samples were taken from mice periodically to analyze the percentage, cell status and cell classification of STAR-T cells in peripheral blood. The specific operations were as follows: every 3-4 days, mice were anesthetized with isoflurane, and about 100uL of blood was taken from the mouse's orbit. The blood samples were subjected to anticoagulation, plasma collection and red blood cell cleavage, and the remaining cells were then subjected to flow staining to detect the ratio of CD4 to CD8 and molecules such as CCR7, CD45RA, PD-1, LAG-3 and TIM-3, which were used for T cell subset analysis and cell status analysis. At the same time, the absolute number of STAR-T cells in the peripheral blood of mice was obtained by flow cytometry or digital PCR. In addition, at the end of the experiment, mice can be dissected to detect the percentage of T cells in other immune organs of mice.

[0239] 6) Methods for assessing T cell safety in animals To evaluate the toxicity and safety of STAR-T cells, we investigated whether STAR-T cells caused side effects in experimental animals. By observing the behavioral state of the mice, analyzing the pathology of the mice, and analyzing sections taken from the vital organs of the mice, we could evaluate whether the reinjected T cells had significant toxicity. At the same time, by analyzing the infiltration of T cells in non-tumor tissues of the mice, we could determine whether the T cells had off-target killing effects on non-tumor tissues of the mice. Furthermore, by detecting the levels of cytokines, such as IL-2, IFN-γ, TNFα, or IL-6, in the blood of the mice, we could determine whether the T cells could cause a systemic cytokine storm.

[0240] 7) Methods for assessing the tumor infiltration ability of T cells The ability of T cells to infiltrate tumors is the core ability to attack solid tumors. To detect the infiltration ability of T cells, tumor tissues are first isolated, then digested and crushed to obtain single cells, and the single cells are subjected to flow staining to detect the proportion of T cells in tumor tissues. At the same time, tumor cells, tumor stromal cells and immune cells in the tumor suspension can be further separated by density gradient centrifugation (e.g., Percoll gradient, Ficoll gradient, etc.) to obtain purified tumor-infiltrating T cells, and their characteristics, such as chemokine receptor expression, T cell exhaustion and others, can be analyzed in detail by sequencing and other methods.

[0241] 8) Results According to the in vitro function results above, 5 × 10 5Raji-luciferase tumor cells were inoculated into 6-8 week old NCG female mice via the tail vein to establish mouse tumor models (Figure 34), and the in vivo function of expressing αβOX40-STAR or mut-STAR T cells was further evaluated. On day 6, tumor-bearing mice were divided into four groups: A: PBS-injected group (injected with equal volume of PBS), B: mut-STAR T cells-injected group, C: αβOX40-STAR T cells-injected group, and D: BBz-CAR-T cells-injected group. Mice in groups B / C / D were inoculated with 5×10 6-cells via the tail vein. 5 TCR T cells were injected into mice in group A, and 200 μL of an equal volume of PBS was injected into mice in group B. In the following weeks, tumor cell growth, in vivo TCR T cell proliferation, and mouse survival were monitored. As shown in Figures 34 and 35, compared with the control group, the αβOX40-STAR T and mut-STAR T cells constructed in this example can significantly extend the survival time of tumor-bearing mice, but after the tumor disappeared and tumor cells were reinjected into the mice at different time points, αβOX40-STAR T and mut-STAR T can properly eliminate tumor cells, the effect of αβOX40-STAR T is better than that of mut-STAR T, and the survival time of mice in the αβOX40-STAR T group is longer than that in the STAR-T group and CAR-T group. Furthermore, as shown in Figure 36, compared with the STAR-T group, the in vivo proliferation effect of αβOX40-STAR T cells was better than that of STAR-T cells, and in the case of tumor reinjection, slight proliferation occurred in αβOX40-STAR T cells, but not in STAR-T cells.

[0242] From the results of the above animal experiments, it can be seen that the in vitro and in vivo effects of the αβOX40-STAR structure were better than those of mut-STAR.

[0243] According to the in vitro function results above, 2 × 10 6Raji-luciferase tumor cells were intraperitoneally inoculated into 6-8 week old NCG female mice to establish mouse tumor models (Figure 37) to further evaluate the in vivo functions of mut-STAR T cells expressing different effects. On day 8, tumor-bearing mice were divided into seven groups: A: PBS-injected group (injected with equal volume of PBS), B: double car, C: double STAR-T cell-injected group, D: αβOX40-STAR T cell-injected group, E: α-del-OX40-STAR-T cell-injected group, F: α-del-(G4S)3-OX40-STAR-T cell-injected group, and G: α-IL7R-STAR-T cell-injected group. Mice in groups B / C / D / E / F / G were injected with 2 × 10 β-glucose monoclonal antibodies (G4S)3-OX40-STAR-T cell injection group via tail vein. 6 TCR T cells were injected into mice in group A, and mice in group B were injected with an equal volume of 200 μL of PBS. Tumor cell growth, in vivo STAR-T cell proliferation, and mouse survival were monitored over the following weeks. As shown in FIG. 37, compared with the control group, the α-del-(G4S)3-OX40-STAR-T cells constructed in this example could significantly kill tumor cells in tumor-bearing mice, and the effect was superior to that of other groups. From the results of animal experiments, it can be seen that the in vitro and in vivo effects of the α-del-(G4S)3-OX40-STAR structure were better than those of mut-STAR.

[0244] Example 2 Effect of constant region N-terminal modifications on STAR 1. Design of STAR receptor constant region domains In this example, hSTAR refers to a STAR comprising a human TCR constant region. hmct STAR refers to a STAR comprising a constant region with cysteine ​​substitutions and transmembrane domain modifications as shown in Example 1. The mouse TCR alpha chain constant region was hmct STAR TCR alpha (SEQ ID NO: 41) and the mouse TCR beta chain constant region was hmct STAR TCRb (SEQ ID NO: 6). Specific structures are shown in FIG. 38.

[0245] To further optimize the design of STAR molecules, the N-terminus of the constant region of STAR molecules was specifically rearranged to obtain good results based on constant region mouserization, cysteine ​​mutations in the α-chain constant region, and hydrophobic amino acid mutations. Rearrangement meant that some sequences were deleted, while some sequences were humanized. The importance of humanization mutations is to reduce the non-human sequences in STAR molecules as much as possible while maintaining the function of STAR molecules, so that the risk of STAR-T cells being rejected by the receptor can be maximally avoided during clinical application.

[0246] Based on amino acid analysis, a schedule of 18 amino acid rearrangements (mouse sequence is DIQNPEPAVYQLKDPRSQ) at the N-terminus of the TCR alpha chain constant region was performed, and it was found that E6D, K13R, R16K and Q18S in the mouse and humanized sequences belong to homologous amino acid substitutions, and the P15S substitution belongs to a non-polar to polar amino acid substitution, so it can be considered that the protein is not at all conservative in the vicinity of this site and could be modified without affecting the protein function. In summary, the amino acid sequence at positions 1 to 14 was retained and humanized, and amino acids at positions 15 to 18 were deleted.

[0247] Based on amino acid analysis, a schedule of 25 amino acid rearrangements (mouse sequence is DLRNVTPPKVSLFEPSKAEIANKQK) at the N-terminus of the TCR β chain constant region was performed, and it was found that only R3K and L12V in the mouse and humanized sequences were homologous amino acid substitutions, while T6F, K9E, S11A, K17E, A21S, N22H and K23T were heterologous amino acid substitutions. Therefore, it can be considered that the properties of the protein are not at all conservative in the vicinity of these sites and could be modified without affecting the function of the protein. In summary, the amino acid sequence at positions 1 to 16 was retained and humanized, and amino acids at positions 17 and 21 to 25 were deleted.

[0248] After N-terminal rearrangement, the TCR alpha chain constant region was Nrec STAR TCRa (SEQ ID NO: 42) and the TCR beta chain constant region was Nrec STAR TCRb (SEQ ID NO: 43). The specific structures are shown in FIG.

[0249] 2. Design of STAR costimulatory factors 1) Combining different optimization methods in STAR To test the effect of costimulatory factors on various STAR functions, we selected the original non-optimized STAR structure (human TCR α / β STAR, hSTAR), hmct STAR based on hSTAR with C-region murine, cysteine ​​and transmembrane modifications, and Nrec STAR based on hmct STAR with N-terminal modifications.

[0250] 2. Design of STAR structures containing costimulatory factors To enhance the toxicity and T cell proliferation persistence of STAR-T cells, according to the present invention, a humanized costimulatory receptor endodomain sequence was introduced at the C-terminus of the STAR constant region (Figure 39) to study the effect on STAR-T cell function. The original non-optimized STAR structure (human TCR α / β STAR, hSTAR), hmct STAR based on hSTAR, and Nrec STAR based on hmct STAR with N-terminal modifications were selected as the STAR constant region structures of the present invention. The costimulatory signaling structures included the intracellular signaling domains of CD40, OX40, ICOS, CD28, 4-1BB and CD27. In the present invention, modifications can be made in the TCR α chain, β chain and αβ chain. In the present invention, costimulatory molecule modifications were made in the TCR αβ chain, as shown in Figure 40.

[0251] 3. CD19-targeted FMC63-STAR-T Function 1) Determination of CD19-targeting antibody sequence The published scFv sequence, FMC63, was chosen for the CD19-targeting antibody heavy chain variable region (anti-CD19 FMC63-VH, SEQ ID NO: 44) and antibody light chain variable region (anti-CD19 FMC63-VL, SEQ ID NO: 45).

[0252] 2) Construction of vectors containing CD19-targeting STAR and costimulatory factors STAR contained two polypeptide chains, specifically, a first polypeptide chain formed by fusing anti-CD19 FMC63-VL to the TCRbC chain of hSTAR / hmct STAR / Nrec STAR, respectively, and a second polypeptide chain formed by fusing anti-CD19 FMC63 VH to the TCRaC chain of hSTAR / hmct STAR / Nrec STAR, respectively. The GM-CSFR signal peptide was used in both chains. The sequences of the two chains of hSTAR / hmct STAR / Nrec STAR were linked via a polypeptide fragment of furin-SGSG-p2A protease cleavage site, transcribed and translated together into a protein, and then cleaved by the corresponding proteases of furin and p2A, finally generating two independent protein chains. The entire gene was inserted into the lentiviral expression vector pHAGE via the restriction endonuclease sites NheI and NotI. The vector was carried with an ampicin resistance gene, an EF1α promoter and an IRES-RFP fluorescent reporter gene. The following plasmids were obtained by cloning, assembling, transformation, sequencing and plasmid extraction of gene fragments: FMC63-hSTAR, FMC63-hmct STAR, FMC63-Nrec STAR.

[0253] Construction of STAR vectors containing costimulatory factors: Based on three CD19-targeting STAR vectors, FMC63-hSTAR, FMC63-hmct STAR and FMC63-Nrec STAR, CD40, OX40, ICOS, CD28, 41BB and CD27 were constructed and the above sequences were obtained by gene synthesis. The costimulatory factors were added to the FMC63-hSTAR, FMC63-hmct STAR and FMC63-Nrec STAR vectors by simultaneously adding the same costimulatory factors to the TCR α and β chains by PCR and homologous recombination. Finally, FMC63-hSTAR-CD40, FMC63-hSTAR-OX40, FMC63-hSTAR-ICOS, FMC63-hSTAR-CD28, FMC63-hSTAR-41BB, FMC63-hSTAR-CD27, FMC63-hmct STAR-CD40, FMC63-hmct STAR-OX40, FMC63-hmct STAR-ICOS, FMC63-hmct STAR-CD28, FMC63-hmct STAR-41BB, FMC63-hmct STAR-CD27, FMC63-Nrec STAR-CD40, FMC63-Nrec STAR-OX40, FMC63-Nrec STAR-ICOS, FMC63-Nrec STAR-CD28, FMC63-Nrec STAR-41BB and FMC63-Nrec STAR-CD27 was constructed.

[0254] 3) Detection of the killing capacity of STARs containing CD19-targeted STARs and costimulatory factors In 24-well plates, uninfected T cells (NC group), FMC63-hSTAR, FMC63-hmct STAR, FMC63-Nrec STAR, FMC63-hSTAR-CD40, FMC63-hSTAR-OX40, FMC63-hSTAR-ICOS, FMC63-hSTAR-CD28, FMC63-hSTAR-41BB, FMC63-hSTAR-CD27, FMC63-hmct STAR-CD40, FMC63-hmct STAR-OX40, FMC63-hmct STAR-ICOS, FMC63-hmct STAR-CD28, FMC63-hmct STAR-41BB, FMC63-hmct STAR-CD27, FMC63-Nrec STAR-CD40, FMC63-Nrec STAR-OX40, FMC63-Nrec STAR-ICOS, FMC63-Nrec STAR-CD28, FMC63-Nrec STAR-41BB and FMC63-Nrec STAR-CD27 were co-cultured with RAJI-luc cells for 24 hours. In a total of 1mL of co-culture system, the number of positive cells of T cells was adjusted to 4E5 according to the RFP positive rate, and the number of RAJI-luc cells was 4E5. After 24 hours of co-culture, the co-cultured cells were mixed evenly, 150μL of suspension was drawn out and added with 70μL of luciferase substrate, and after shaking at low speed in the dark for 10 minutes, the fluorescence value was detected by a multi-function microplate reader, and the target cell killing effect of each group was calculated. The results showed that the killing efficiency of hSTAR was significantly lower than that of hmct STAR and Nrec STAR, among which Nrec STAR was the highest. The results of the same STAR containing costimulatory factors showed that OX40 and ICOS could significantly increase the killing effect of STAR, while other costimulatory factors had no significant effect on the killing ability of STAR, and 41BB reduced the killing function of STAR, but the difference was not significant (Figure 41).

[0255] Figure 4. Detection of nuclear RelB levels in STAR containing CD19-targeted STARs and costimulatory factors. The following viruses FMC63-hSTAR, FMC63-hmct STAR, FMC63-Nrec STAR, FMC63-hSTAR-CD40, FMC63-hSTAR-OX40, FMC63-hSTAR-ICOS, FMC63-hSTAR-CD28, FMC63-hSTAR-41BB, FMC63-hSTAR-CD27, FMC63-hmct STAR-CD40, FMC63-hmct STAR-OX40, FMC63-hmct STAR-ICOS, FMC63-hmct STAR-CD28, FMC63-hmct STAR-41BB, FMC63-hmct STAR-CD27, FMC63-Nrec STAR-CD40, FMC63-Nrec STAR-OX40, FMC63-Nrec STAR-ICOS, FMC63-Nrec STAR-CD28, FMC63-Nrec STAR-41BB and FMC63-Nrec STAR-CD27 were infected into Jurkat cells at a titer of MOI=1, and 4 days after infection, T cell lines and CD19 protein were co-cultured in 12-well plates (2 μg / mL, 500 μL was coated on 12-well plates and left in a 4° C. refrigerator overnight), where STAR-T cells were 4E6 and target cells were 2E5 (target cells were seeded into 12-well plates 1 day before). Cells were cultured for 6 hours, then harvested for nuclear protein extraction and nuclear protein was detected by Western blotting for nuclear RelB levels. According to the results, as shown in Figure 42, the nuclear RelB levels were very low in the FMC63-hSTAR, FMC63-hmct STAR and FMC63-Nrec STAR groups without costimulatory factors, consistent with the uninfected STAR-T group; after the addition of costimulatory factors, other costimulatory factors except CD28 significantly increased the nuclear RelB levels, among which 41BB improved the nuclear RelB levels the most.

[0256] 4.CD19 targeting 334-STAR-T function 1) Determination of CD19-targeting antibody sequence The 334 antibody sequences developed by the present invention were selected for the CD19-targeting antibody heavy chain variable region (anti-CD19 334-VH, SEQ ID NO: 46) and antibody light chain variable region (anti-CD19 334-VL, SEQ ID NO: 47).

[0257] 2) Construction of vectors containing CD19-targeting STAR and costimulatory factors STAR contained two polypeptide chains, specifically, the first polypeptide chain formed by fusing anti-CD19 334-VL with the TCRbC chain of hSTAR / hmct STAR / Nrec STAR, respectively, and the second polypeptide chain formed by fusing anti-CD19 334 VH with the TCRaC chain of hSTAR / hmct STAR / Nrec STAR, respectively. The GM-CSFR signal peptide was used in both chains. The sequences of the two chains of hmct STAR / Nrec STAR were linked via a polypeptide fragment of furin-SGSG-p2A protease cleavage site, transcribed and translated together into a protein, and then cleaved by the corresponding proteases of furin and p2A, finally generating two independent protein chains. The whole gene was inserted into the lentiviral expression vector pHAGE via the restriction endonuclease sites NheI and NotI. The vector was carried with an ampicin resistance gene, an EF1α promoter and an IRES-RFP fluorescent reporter gene. By cloning, assembling, transforming, sequencing and plasmid extraction of gene fragments, the following plasmids were obtained: 334-hmct STAR, 334-Nrec STAR.

[0258] Construction of STAR vectors containing costimulatory factors: Based on the CD19-targeting STAR vectors 334-hmct STAR and 334-Nrec STAR, costimulatory factor OX40 was constructed on them, and the above sequence was obtained by gene synthesis. The same costimulatory factor was added to the 334-hmct STAR and 334-Nrec STAR vectors by simultaneously adding the same costimulatory factor to the TCR α and β chains by PCR and homologous recombination. Finally, 334-hmct STAR-OX40 and 334-Nrec STAR-OX40 were constructed.

[0259] 3) Detection of the killing capacity of STARs containing CD19-targeted STARs and costimulatory factors In a 24-well plate, uninfected T cells (NC group), 334-hmct STAR, 334-Nrec STAR, 334-hmct STAR-OX40 and 334-Nrec STAR-OX40 were co-cultured with RAJI-luc cells for 24 hours. In a total of 1 mL of co-culture system, the number of positive cells of T cells was adjusted to 4E5 according to the RFP positive rate, and the number of RAJI-luc cells was 4E5. After 24 hours of co-culture, the co-cultured cells were mixed evenly, 150 μL of suspension was sucked out and added with 70 μL of luciferase substrate, and after shaking at low speed in the dark for 10 minutes, the fluorescence value was detected by a multi-function microplate reader, and the target cell killing effect of each group was calculated. The results showed that compared with hmct STAR and Nrec STAR, OX40 could significantly increase the killing efficiency. Furthermore, OX40 can significantly increase the proliferation capacity and nuclear RelB levels of STAR-T cells. See Figure 43.

[0260] 5. CD19 and CD20 Targeted STAR-T Function 1) Determination of CD19 and CD20 targeting antibody sequences CD19-targeting antibody heavy chain variable region (anti-CD19 FMC63-VH, SEQ ID NO: 44) and antibody light chain variable region (anti-CD19 FMC63-VL, SEQ ID NO: 45); CD20-targeting antibody heavy chain variable region (anti-CD20 2C6-VH, SEQ ID NO: 54) and antibody light chain variable region (anti-CD20 2C6-VL, SEQ ID NO: 55).

[0261] 2) Construction of vectors containing CD19 and CD20 targeting STAR and costimulatory factors STAR contained two polypeptide chains, specifically, a first polypeptide chain formed by fusing anti-CD20 2C6 VL-(G4S)3-VH to the TCRbC chain of hmct STAR / Nrec STAR, respectively, and a second polypeptide chain formed by fusing anti-CD19 FMC63 VL-(G4S)3-VH to the TCRaC chain of hmct STAR / Nrec STAR, respectively. The GM-CSFR signal peptide was used in both chains. The sequences of the two chains of hmct STAR / Nrec STAR were linked via a polypeptide fragment of furin-SGSG-p2A protease cleavage site, transcribed and translated together into a protein, and then cleaved by the corresponding proteases of furin and p2A, finally generating two independent protein chains. The entire gene was inserted into the lentiviral expression vector pHAGE via the restriction endonuclease sites NheI and NotI. The vector was carried with an ampicin resistance gene, an EF1α promoter and an IRES-RFP fluorescent reporter gene. The following plasmids were obtained by cloning, assembling, transformation, sequencing and plasmid extraction of gene fragments: FMC63-2C6-hmct STAR and FMC63-2C6-Nrec STAR.

[0262] Construction of STAR vectors containing costimulatory factors: Based on CD19 and CD20 targeting STAR vectors FMC63-2C6-hmct STAR and FMC63-2C6-Nrec STAR, costimulatory factor OX40 was constructed on them, and the above sequence was obtained by gene synthesis. The same costimulatory factor was added to the TCR α and β chains simultaneously by PCR and homologous recombination, and the costimulatory factor was added to the FMC63-2C6-hmct STAR and FMC63-2C6-Nrec STAR vectors. Finally, FMC63-2C6-hmct STAR-OX40 and FMC63-2C6-Nrec STAR-OX40 were constructed.

[0263] 3) Detection of the killing capacity of STARs including CD19- and CD20-targeted STARs and costimulatory factors In a 24-well plate, uninfected T cells (NC group), FMC63-2C6-hmct STAR, FMC63-2C6-Nrec STAR, FMC63-2C6-hmct STAR-OX40 and FMC63-2C6-Nrec STAR-OX40 were co-cultured with RAJI-luc cells for 24 hours. In a total of 1 mL of co-culture system, the number of positive cells of T cells was adjusted to 4E5 according to the RFP positive rate, and the number of RAJI-luc cells was 4E5. After 24 hours of co-culture, the co-cultured cells were mixed evenly, 150 μL of suspension was sucked out and added with 70 μL of luciferase substrate, and after shaking at low speed in the dark for 10 minutes, the fluorescence value was detected by a multi-function microplate reader, and the target cell killing effect of each group was calculated. The results showed that compared with hmct STAR and Nrec STAR, OX40 could significantly increase the killing efficiency. Furthermore, OX40 can significantly increase the proliferation capacity and nuclear RelB levels of STAR-T cells. See Figure 44.

[0264] 4) Improved proliferation capacity of CD19- and CD20-targeted STARs when costimulatory factors are added only to the TCR α chain The first polypeptide chain was formed by fusing anti-CD20 2C6 VL-(G4S)3-VH to the TCRβC of the hmct STAR structure (SEQ ID NO: 6), and the second polypeptide chain was formed by fusing anti-CD19 FMC63 VL-(G4S)3-V to the TCRαC constant region of hmct STAR (SEQ ID NO: 26) lacking the native endodomain and with the OX40 costimulatory domain added to the C-terminus of the constant region. The GM-CSFR signal peptide was used in both chains. The sequences of the two chains of STAR were linked via a polypeptide fragment of the furin-SGSG-p2A protease cleavage site, transcribed and translated together into a protein (SEQ ID NO: 58), then cleaved by the corresponding proteases of furin and p2A, finally generating two independent protein chains. Thus, a CD19 and CD20 targeting STAR was obtained in which the costimulatory factor was linked only to the TCRα chain: a(G4S)3OX40. A comparison of killing and proliferation capabilities was made between these STARs and the CD19- and CD20-targeted hmct STAR abOX40, in which costimulatory factors are linked to both the TCR α and β chains. The results are shown in Figure 45. a(G4S)3OX40 is superior to abOX40.

[0265] [Sequence table] SEQ ID NO: 1: Amino acid sequence of the wild-type human TCR alpha constant region DIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS* SEQ ID NO:2 Amino acid sequence of wild-type human TCR β constant region DLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVK RKDF* SEQ ID NO:3 Amino acid sequence of wild-type mouse TCR alpha constant region DIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKTVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLSVMGLRILLLKVAGFNLLMTLRLWSS SEQ ID NO: 4: Amino acid sequence of wild-type mouse TCR β constant region DLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVSTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNS SEQ ID NO: 5 Mouse T-cell receptor alpha chain constant region with cysteine ​​substitution (Mouse TCRaC-Cys) DIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLSVMGLRILLLKVAGFNLLMTLRLWSS SEQ ID NO:6 Mouse T cell receptor beta chain constant region with cysteine ​​substitution (Mouse TCRβC-Cys) DLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNS SEQ ID NO: 7 Mouse T cell receptor alpha chain constant region with hydrophobic amino acid substitutions (mouse TCRaC-TM9) DIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKTVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLLVIVLRILLLKVAGFNLLMTLRLWSS SEQ ID NO: 8 Mouse T cell receptor alpha chain constant region with a cysteine ​​substitution in the transmembrane domain (Mouse TCRaC-Arg mut) DIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLLVIVLRILLLRVAGFNLLMTLRLWSS SEQ ID NO: 9 Mouse T cell receptor beta chain constant region with cysteine ​​substitutions in the transmembrane and endodomains (mouse TCRβC-Arg mut) DLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGRATLYAVLVSTLVVMAMVRRRNS SEQ ID NO: 10 Amino acid sequence of CD40 endodomain KKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERO

[0266] SEQ ID NO: 11 Amino acid sequence of OX40 endodomain RRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI SEQ ID NO: 12 Amino acid sequence of ICOS endodomain KKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL SEQ ID NO: 13: Amino acid sequence of CD28 endodomain RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS SEQ ID NO: 14: Amino acid sequence of 4-1BB endodomain KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL SEQ ID NO: 15: Amino acid sequence of CD27 endodomain QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP SEQ ID NO: 16 Amino acid sequence of the G4S linker GGGGS SEQ ID NO:17 Amino acid sequence of the (G4S)2 linker GGGGSGGGGS SEQ ID NO:18 Amino acid sequence of the (G4S)3 linker GGGGSGGGGSGGGGS SEQ ID NO:19 Amino acid sequence of the (G4S)4 linker GGGGSGGGGSGGGGSGGGGS SEQ ID NO:20 Amino acid sequence of the (G4S)5 linker GGGGSGGGGSGGGGSGGGGSGGGGS

[0267] SEQ ID NO:21 Amino acid sequence of the (G4S)6 linker GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS SEQ ID NO:22 Amino acid sequence of the (G4S)7 linker GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS SEQ ID NO:23 Amino acid sequence of the (G4S)8 linker GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS SEQ ID NO:24 Amino acid sequence of the (G4S)9 linker GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS SEQ ID NO:25 Amino acid sequence of the (G4S)10 linker GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS SEQ ID NO: 26 Endodomain-deleted mouse T cell receptor α chain constant region with cysteine ​​substitutions and hydrophobic modifications (mouse TCRαC-del mut) DIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLLVIVLRILLLKVAGFNLLMTLRLW SEQ ID NO: 27 Endodomain-deleted mouse T cell receptor beta chain constant region with cysteine ​​substitution (mouse TCRβC-del mut) DLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAM SEQ ID NO: 28 Amino acid sequence of human CD3γ MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLRRN SEQ ID NO: 29 Amino acid sequence of human CD3δ MEHSTFLSGLVLATLLSQVSPFKIPIEELEDRVFVNCNTSITWVEGTVGTLLSDITRLDLGKRILDPRGIYRCNGTDIYKDKESTVQVHYRMCQSCVELDPATVAGIIVTDVIATLLLALGVFCFAGHETGRLSGAADTQALLRNDQVYQPLRDRDDAQYSHLGGNWARNK SEQ ID NO: 30 Amino acid sequence of human CD3ε MQSGTHWRVLGLCLLSVGVWGQDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGS KPEDANFYLYLRARVCENCMEMDVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPPVPNPDYEPIRKGQRDLYSGLNQRRI

[0268] SEQ ID NO: 31 Amino acid sequence of human CD3ζ MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR SEQ ID NO: 32 Amino acid sequence of human IL-2β receptor endodomain NCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLPLNTDAYLSLQELQGQDPTHLV SEQ ID NO: 33: Amino acid sequence of human IL-7α receptor endodomain KKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSSNQEEAYVTMSSFYQNQ SEQ ID NO: 34: Amino acid sequence of human IL-21 receptor endodomain SLKTHPLWRLWKKIWAVPSPERFFMPLYKGCSGDFKKWVGAPFTGSSLELGPWSPEVPSTLEVYSCHPPRSPAKRLQLTELQEPAELVESDGVPKPSFWPTAQNSGGSAYSEERDRPYGLVSIDTVTVLDAEGPCTWPCSCE DDGYPALDLDAGLEPSPGLEDPLLDAGTTVLSCGCVSAGSPGGLGGPLGSLLDRLKPPLADGEDWAGGLPWGGRSPGGVSESEAGSPLAGLDMDTFDSGFVGSDCSSPVECDFTSPGDEGPPRSYLRQWVVIPPPLSSPGPQAS SEQ ID NO: 35 Amino acid sequence of human STAT5 activating portion YRHQ SEQ ID NO: 36: Amino acid sequence of human IL-2β receptor endodomain and human STAT5 activation portion NCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLPLNTDAYLSLQELQGQDPTHLVGGGGSYRHQ SEQ ID NO: 37 Amino acid sequence of human IL-7α receptor endodomain and human STAT5 activation portion KKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSSNQEEAYVTMSSFYQNQGGGGSYRHQ SEQ ID NO: 38 Amino acid sequence of anti-CD20 OFA ScFv EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKGGGGSGGGGSGGGS EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS SEQ ID NO: 39 Amino acid sequence of anti-CD19 FMC63 ScFv DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGGGGSGGGGSGGGG SEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS SEQ ID NO: 40 Amino acid sequence of red fluorescent protein MASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSL QDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASTERMYPEDGALKGEIKMRLKLKDGGHYDAEVKTTYMAKKPVQLPGAYKTDIKLDITSHNEDYTIVEQYERAEGRHSTGA*

[0269] SEQ ID NO: 41 Mouse TCRaC-Cys-TM9 (hmct STAR TCRaC) DIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLLVIVLRILLLKVAGFNLLMTLRLWSS SEQ ID NO: 42 Mouse TCRaC-Cys-TM9-N.Rec (Nrec STAR TCRaC) DIQNPDPAVYQLRDDSTLCLFTDFDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLLVIVLRILLLKVAGFNLLMTLRLWSS SEQ ID NO: 43 Mouse T cell receptor beta chain constant region with N-terminal modifications and cysteine ​​substitutions (Mouse TCRbC-Cys-N.Rec, Nrec STAR TCRbC) DLKNVFPPEVAVFEPSAEIATLVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNS SEQ ID NO: 44 Anti-CD19 FMC63 VH EVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS SEQ ID NO: 45 Anti-CD19 FMC63 VL DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIT SEQ ID NO: 46 Anti-CD19 334 VH QVQLQQSGAELVRPGASVKLSCKALGFIFTDYEIHWVKQTPVHGLEWIGAFHPGSGGSAYNQKFKGKATLTADKSSSTAYMELSSLTFEDSAVYHCTRQLGPDWGQGTLVTVS SEQ ID NO: 47 Anti-CD19 334 VL DVVMTQTPLTLSVTIGQPASISCKSSQSLLESDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLRISRVEAEDLGVYYCWQGTQFPWTFGGGTKLEIK SEQ ID NO: 48 Endodomain-deleted mouse T cell receptor alpha chain constant region with N-terminal modifications, cysteine ​​substitutions and hydrophobic modifications in the transmembrane domain DIQNPDPAVYQLRDDSTLCLFTDFDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLLVIVLRILLLKVAGFNLLMTLRLW SEQ ID NO: 49 Endodomain-deleted mouse T cell receptor beta chain constant region with N-terminal modifications and cysteine ​​substitutions DLKNVFPPEVAVFEPSAEIATLVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAM SEQ ID NO: 50 Amino acid sequence of the wild type human TCR gamma chain constant region: DKQLDADVSPKPTIFLPSIAETKLQKAGTYLCLLEKFFPDVIKIHWQEKKSNTILGSQEGNTMKTNDTYMKFSWLTVPEKSLDKEHRCIVRHENNKNGVDQEIIFPPIKTDVITMDPKDNCSKDANDTLLLQLTNTSAYYMYLLLLLKSVVVYFAIITCCLLRRTAFCCNGEKS

[0270] SEQ ID NO: 51 Amino acid sequence of wild type mouse TCR gamma chain constant region: XKRLDADISPKPTIFLPSVAETNLHKTGTYLCLLEKFFPDVIRVYWKEKDGNTILDSQEGDTLKTNDTYMKFSWLTVPERAMGKEHRCIVKHENNKGGADQEIFFPSIKKVAVSTKPTTCWQDKNDVLQLQFTITSAYYTYLLLLLKSVIYLAIISFSLLRRTSVCGNEKKS SEQ ID NO: 52 Amino acid sequence of the wild type human TCR δ chain constant region: XSQPHHTKPSVFVMKNGTNVACLVKEFYPKDIRINLVSSKKITEFDPAIVISPSGKYNAVKLGKYEDSNSVTCSVQHDNKTVHSTDFEVKTDSTDHVKPKETENTKQPSKSCHKPKAIVHTEKVNMMSLTVLGLRMLFAKTVAVNFLLTAKLFFL* SEQ ID NO: 53: Amino acid sequence of wild-type mouse TCR δ chain constant region XSQPPAKPSVFIMKNGTNVACLVKDFYPKEVTISLRSSKIVEFDPAIVISPSGKYSAVKLGQYGDSNSVTCSVQHNSETVHSTDFEPYANSFNNEKLPEPENDTQISEPCYGPRVTVHTEKVNMMSLTVLGLRLLFAKTIAINFLLTVKLFF* SEQ ID NO: 54 Anti-CD20 2C6 VH AVQLVESGGGLVQPGRSLRLSCAASGFTFGDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCTKDNQYGSGSTYGLGVWGQGTLVTVSS SEQ ID NO: 55 Anti-CD20 2C6 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK SEQ ID NO: 56 Anti-CD20 OFA VH EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS SEQ ID NO: 57 Anti-CD20 OFA VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK SEQ ID NO: 58 CD19 and CD20 targeting a(G4S)3OX40 MLLLVTSLLLCELPHPAFLLIPEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIKGGGGSGGGGSGGGGSAVQLVESGGGLVQPGRSLRLSCAASGFTFGDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCTKDNQYGSGSTYGLGVWGQGTLVTVSSEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNSRRKRSGSGATNFSLLKQAGDVEENPGPMLLLVTSLLLCELPHPAFLLIPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSDIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLLVIVLRILLLKVAGFNLLMTLRLWGGGGSGGGGSGGGGSRRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI* SEQ ID NO:59 TCR α chain of CD19- and CD20-targeted a(G4S)3OX40 DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIT GGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAI YYCAKHYYYGGSYAMDYWGQGTSVTVSSDIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKE TNATYPSSDVPPCDATLTEKSFETDMNLNFQNLLVIVLRILLLKVAGFNLLMTLRLWGGGGSGGGGSGGGGSRRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI SEQ ID NO: 60 TCR beta chain of a(G4S)3OX40 targeting CD19 and CD20 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKV EIKGGGGSGGGGSGGGGSAVQLVESGGGLVQPGRSLRLSCAASGFTFGDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLR AEDTALYYCTKDNQYGSGSTYGLGVWGQGTLVTVSSEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNY SYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNS

Claims

1. A T cell receptor (αβ TCR) comprising a TCR α chain and a TCR β chain, wherein at least one functional domain is linked to the C-terminus of the TCR α chain and / or the TCR β chain of the αβ TCR; the TCR α chain comprises a first constant region and a first antigen-binding region, and the TCR β chain comprises a second constant region and a second antigen-binding region; the first antigen-binding region specifically binds to a first antigen and the second antigen-binding region specifically binds to a second antigen, or the first antigen-binding region and the second antigen-binding region in combination with each other specifically bind to the first antigen and the second antigen; the first antigen is CD19 and the second antigen is CD20, or the first antigen is CD20 and the second antigen is CD19; The functional domain is OX40. A modified T cell receptor,

2. The modified T cell receptor of claim 1 , wherein the antigen-binding region is derived from an antibody.

3. A modified T cell receptor as described in claim 1 or 2, wherein the natural endodomain of the TCR α chain and / or the TCR β chain of the αβ TCR is missing.

4. A modified T cell receptor as described in claim 3, wherein in the αβ TCR, the functional domain is linked directly or via a linker to the C-terminus of the TCR α chain and / or the TCR β chain which lacks a natural endodomain.

5. The linker is (G 4 S) n, wherein n represents an integer from 1 to 10.

6. The modified T cell receptor of claim 5, wherein n is 3.

7. The modified T cell receptor of any one of claims 1 to 6, wherein at least one functional domain is linked to the C-terminus of only one of the TCRα and TCRβ chains of the αβ TCR.

8. The modified T cell receptor of claim 7 , wherein at least one functional domain is linked to the C-terminus of the TCR α chain of the αβ TCR.

9. The modified T cell receptor of claim 8 , wherein the native endodomain of the TCR α chain is deleted.

10. The modified T cell receptor of claim 9 , wherein the functional domain is linked directly or via a linker to the C-terminus of the TCR α chain lacking the native endodomain.

11. The linker is (G 4 S) n, wherein n represents an integer from 1 to 10.

12. The modified T cell receptor of claim 11, wherein n is 3.

13. The modified T cell receptor of claim 7 , wherein at least one functional domain is linked to the C-terminus of the TCR β chain of the αβ TCR.

14. The modified T cell receptor of claim 13 , wherein the native endodomain of the TCR β chain is deleted.

15. The modified T cell receptor of claim 14, wherein the functional domain is linked directly or via a linker to the C-terminus of the TCR β chain lacking a native endodomain.

16. The linker is (G 4 S) n, wherein n represents an integer from 1 to 10.

17. The modified T cell receptor of claim 16, wherein n is 3.

18. 7. The modified T cell receptor of claim 1, wherein at least one functional domain is linked to the C-terminus of both the TCR α chain and the TCR β chain of the αβ TCR.

19. The modified T cell receptor of claim 18 , wherein the native endodomains of both the TCR α chain and the TCR β chain are deleted.

20. The modified T cell receptor of claim 19, wherein the functional domain is linked directly or via a linker to the C-terminus of both the TCR α chain and the TCR β chain, which lack the native endodomain.

21. The linker is (G 4 S) n, wherein n represents an integer from 1 to 10.

22. The modified T cell receptor of claim 21, wherein n is 3.

23. 23. The modified T cell receptor of any one of claims 1 to 22, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more functional domains are linked to the C-terminus of the TCR α chain and / or TCR β chain of the αβ TCR.

24. 24. The modified T cell receptor of any one of claims 1 to 23, wherein the first constant region is a native human TCR α chain constant region or a native mouse TCR α chain constant region.

25. 24. The modified T cell receptor of any one of claims 1 to 23, wherein the first constant region is a modified TCR α chain constant region.

26. 26. The modified T cell receptor of claim 25, wherein the modified TCR alpha chain constant region is derived from a mouse TCR alpha chain constant region in which the amino acid at position 48, threonine (T), is mutated to cysteine ​​(C) compared to the wild-type mouse TCR alpha chain constant region.

27. 26. The modified T cell receptor of claim 25, wherein the modified TCR α-chain constant region is derived from a mouse TCR α-chain constant region in which, compared to the wild-type mouse TCR α-chain constant region, the amino acid serine (S) at position 112 has been mutated to leucine (L), the methionine (M) at position 114 has been mutated to isoleucine I, and the amino acid glycine (G) at position 115 has been mutated to valine (V).

28. The modified T cell receptor of claim 25, wherein the modified TCR α-chain constant region is derived from a mouse TCR α-chain constant region in which, compared to a wild-type mouse TCR α-chain constant region, the amino acid at position 6, E, is replaced with D, the amino acid at position 13, K, is replaced with R, and amino acids at positions 15 to 18 are deleted.

29. 26. The modified T cell receptor of claim 25, wherein the modified TCR α-chain constant region is derived from a mouse TCR α-chain constant region in which, compared to the wild-type mouse TCR α-chain constant region, the amino acid at position 48, threonine (T), is mutated to cysteine ​​(C), the amino acid at position 112, serine (S), is mutated to leucine (L), the amino acid at position 114, methionine (M), is mutated to isoleucine (I), and the amino acid at position 115, glycine (G), is mutated to valine (V).

30. 26. The modified T cell receptor of claim 25, wherein the modified TCR α-chain constant region is derived from a mouse TCR α-chain constant region in which, compared to a wild-type mouse TCR α-chain constant region, the amino acid at position 6, E, is substituted with D, the amino acid at position 13, K, is substituted with R, the amino acids at positions 15 to 18, the amino acid at position 48, threonine (T), is mutated to cysteine ​​(C), the amino acid at position 112, serine (S), is mutated to leucine (L), the amino acid at position 114, methionine (M), is mutated to isoleucine (I), and the amino acid at position 115, glycine (G), is mutated to valine (V).

31. The modified T cell receptor of any one of claims 1 to 23, wherein the first constant region comprises an amino acid sequence represented by one of SEQ ID NOs: 1, 3, 5, 7, 8, 26, 41, 42, and 48.

32. 32. The modified T cell receptor of any one of claims 1 to 31, wherein the second constant region is a native human TCR β chain constant region or a native mouse TCR β chain constant region.

33. 32. The modified T cell receptor of any one of claims 1 to 31, wherein the second constant region is a modified TCR β chain constant region.

34. 34. The modified T cell receptor of claim 33, wherein the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which amino acid 56, serine (S), is mutated to cysteine ​​(C) compared to the wild-type mouse TCR β chain constant region.

35. 34. The modified T cell receptor of claim 33, wherein the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which, compared to a wild-type mouse TCR β chain constant region, the amino acid at position 3, R, is replaced with K, the amino acid at position 6, T, is replaced with F, the amino acid at position 9, K, is replaced with E, the amino acid at position 11, S, is replaced with A, the amino acid at position 12, L, is replaced with V, and amino acids at positions 17 and 21 to 25 are deleted.

36. 34. The modified T cell receptor of claim 33, wherein the modified TCR β chain constant region is derived from a mouse TCR β chain constant region in which, compared to a wild-type mouse TCR β chain constant region, the amino acid serine (S) at position 56 is mutated to cysteine ​​(C), the amino acid R at position 3 is substituted with K, the amino acid T at position 6 is substituted with F, the amino acid K at position 9 is substituted with E, the amino acid S at position 11 is substituted with A, the amino acid L at position 12 is substituted with V, and the amino acids at positions 17 and 21 to 25 are deleted.

37. 32. A modified T cell receptor according to any one of claims 1 to 31, comprising an amino acid sequence set forth in one of SEQ ID NOs: 2, 4, 6, 9, 27, 43 and 49.

38. 38. The modified T cell receptor of any one of claims 1 to 37, wherein the antigen-binding region is derived from an antibody.

39. 39. The modified T cell receptor of any one of claims 1 to 38, wherein the antigen-binding region comprises a single chain antibody or a single domain antibody.

40. The modified T cell receptor of claim 39, wherein the single chain antibody comprises a heavy chain variable region and a light chain variable region linked by a linker, the linker being (G 4 S) n , where n is an integer from 1 to 10.

41. The modified T cell receptor of claim 40, wherein n is 1 or 3.

42. 42. The modified T cell receptor of any one of claims 1 to 41, wherein the antigen-binding region that specifically binds to CD19 comprises a heavy chain variable region amino acid sequence represented by SEQ ID NO:44 and a light chain variable region amino acid sequence represented by SEQ ID NO:

45.

43. 42. The modified T cell receptor of any one of claims 1 to 41, wherein the antigen-binding region that specifically binds to CD19 comprises a heavy chain variable region amino acid sequence represented by SEQ ID NO:46 and a light chain variable region amino acid sequence represented by SEQ ID NO:

47.

44. 42. The modified T cell receptor of any one of claims 1 to 41, wherein the antigen-binding region that specifically binds to CD19 comprises the scFv amino acid sequence set forth in SEQ ID NO:

39.

45. 45. The modified T cell receptor of any one of claims 1 to 44, wherein the antigen-binding region that specifically binds to CD20 comprises a heavy chain variable region amino acid sequence represented by SEQ ID NO:54 and a light chain variable region amino acid sequence represented by SEQ ID NO:

55.

46. 45. The modified T cell receptor of any one of claims 1 to 44, wherein the antigen-binding region that specifically binds to CD20 comprises a heavy chain variable region amino acid sequence represented by SEQ ID NO:56 and a light chain variable region amino acid sequence represented by SEQ ID NO:

57.

47. 45. The modified T cell receptor of any one of claims 1 to 44, wherein the antigen-binding region that specifically binds to CD20 comprises the scFv amino acid sequence set forth in SEQ ID NO:

38.

48. The modified T cell receptor of claim 1 , wherein the TCR α chain comprises the amino acid sequence represented by SEQ ID NO:59 and the TCR β chain comprises the amino acid sequence represented by SEQ ID NO:

60.

49. i) the first antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, while the second antigen-binding region comprises an antibody light chain variable region that specifically binds to the first antigen and an antibody light chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region combine with each other to specifically bind to both the first antigen and the second antigen; or ii) the first antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody light chain variable region that specifically binds to the second antigen, while the second antigen-binding region comprises an antibody light chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region combine with each other to specifically bind to both the first antigen and the second antigen; or iii) the first antigen-binding region comprises an antibody light chain variable region that specifically binds to the first antigen and an antibody light chain variable region that specifically binds to the second antigen, while the second antigen-binding region comprises an antibody heavy chain variable region that specifically binds to the first antigen and an antibody heavy chain variable region that specifically binds to the second antigen, such that the first antigen-binding region and the second antigen-binding region are combined with each other to specifically bind to both the first antigen and the second antigen; the first antigen is CD19 and the second antigen is CD20, or the first antigen is CD20 and the second antigen is CD19; A modified T cell receptor according to any one of claims 1 to 38.

50. 50. An isolated therapeutic immune cell comprising a modified T cell receptor according to any one of claims 1 to 49.

51. 51. The therapeutic immune cell of claim 50, which is a T cell or a NK cell.

52. 52. A pharmaceutical composition comprising the therapeutic immune cells of claim 50 or 51 and a pharma- ceutically acceptable carrier.

53. 53. Use of a therapeutic immune cell according to claim 50 or 51, or a pharmaceutical composition according to claim 52, in the preparation of a medicament for treating cancer in a subject.

Citation Information

Patent Citations

  • Chimeric T cell receptor STAR and application thereof

    CN110818802A

  • T cell receptor fusion proteins and uses thereof

    CN110964122A

  • Anti-Human Papillomavirus 16 E7 T Cell Receptor

    JP2017524372A

  • Chimeric antibody / T cell receptor constructs and uses thereof

    JP2019500848A

  • Cancer treatment using chimeric T cell receptor proteins with multiple specificities

    JP2020506700A